

Form 5500 Department of the Treasury Internal Revenue Service Department of Labor Employee Benefits Security Administration Pension Benefit Guaranty Corporation	Annual Return/Report of Employee Benefit Plan This form is required to be filed for employee benefit plans under sections 104 and 4065 of the Employee Retirement Income Security Act of 1974 (ERISA) and sections 6057(b) and 6058(a) of the Internal Revenue Code (the Code). ▶ Complete all entries in accordance with the instructions to the Form 5500.	OMB Nos. 1210-0110 1210-0089 2025 This Form is Open to Public Inspection
--	---	---

Part I	Annual Report Identification Information
For calendar plan year 2025 or fiscal plan year beginning 01/01/2025 and ending 12/31/2025	
A	This return/report is for: ☐ a multiemployer plan ☐ a multiple-employer plan (Filers checking this box must provide participating employer information in accordance with the form instructions.) ☒ a single-employer plan ☐ a DFE (specify) _____
B	This return/report is: ☐ the first return/report ☐ the final return/report ☐ an amended return/report ☐ a short plan year return/report (less than 12 months)
C	If the plan is a collectively-bargained plan, check here. ▶ ☐
D	Check box if filing under: ☒ Form 5558 ☐ automatic extension ☐ the DFVC program ☐ special extension (enter description)
E	If this is a retroactively adopted plan permitted by SECURE Act section 201, check here. ▶ ☐

Part II	Basic Plan Information—enter all requested information
1a	Name of plan AGIOS PHARMACEUTICALS 401(K) PLAN
1b	Three-digit plan number (PN) ▶ 001
1c	Effective date of plan 06/01/2009
2a	Plan sponsor's name (employer, if for a single-employer plan) Mailing address (include room, apt., suite no. and street, or P.O. Box) City or town, state or province, country, and ZIP or foreign postal code (if foreign, see instructions) AGIOS PHARMACEUTICALS 88 SIDNEY STREET 2ND FLOOR CAMBRIDGE, MA 02139
2b	Employer Identification Number (EIN) 26-0662915
2c	Plan Sponsor's telephone number 617-649-8600
2d	Business code (see instructions) 541700

Caution: A penalty for the late or incomplete filing of this return/report will be assessed unless reasonable cause is established.

Under penalties of perjury and other penalties set forth in the instructions, I declare that I have examined this return/report, including accompanying schedules, statements and attachments, as well as the electronic version of this return/report, and to the best of my knowledge and belief, it is true, correct, and complete.

SIGN HERE	Filed with authorized/valid electronic signature.	07/17/2026	ALISON CONNELLY
	Signature of plan administrator	Date	Enter name of individual signing as plan administrator
SIGN HERE			
	Signature of employer/plan sponsor	Date	Enter name of individual signing as employer or plan sponsor
SIGN HERE			
	Signature of DFE	Date	Enter name of individual signing as DFE

3a Plan administrator's name and address ☒ Same as Plan Sponsor	3b Administrator's EIN 3c Administrator's telephone number
4 If the name and/or EIN of the plan sponsor or the plan name has changed since the last return/report filed for this plan, enter the plan sponsor's name, EIN, the plan name and the plan number from the last return/report: a Sponsor's name c Plan Name	4b EIN 4d PN
5 Total number of participants at the beginning of the plan year	5 782
6 Number of participants as of the end of the plan year unless otherwise stated (welfare plans complete only lines 6a(1) , 6a(2) , 6b , 6c , and 6d). a(1) Total number of active participants at the beginning of the plan year a(2) Total number of active participants at the end of the plan year b Retired or separated participants receiving benefits..... c Other retired or separated participants entitled to future benefits d Subtotal. Add lines 6a(2) , 6b , and 6c e Deceased participants whose beneficiaries are receiving or are entitled to receive benefits. f Total. Add lines 6d and 6e g(1) Number of participants with account balances as of the beginning of the plan year (only defined contribution plans complete this item) g(2) Number of participants with account balances as of the end of the plan year (only defined contribution plans complete this item) h Number of participants who terminated employment during the plan year with accrued benefits that were less than 100% vested.....	6a(1) 491 6a(2) 540 6b 0 6c 271 6d 811 6e 0 6f 811 6g(1) 758 6g(2) 795 6h 0
7 Enter the total number of employers obligated to contribute to the plan (only multiemployer plans complete this item)	7

8a If the plan provides pension benefits, enter the applicable pension feature codes from the List of Plan Characteristic Codes in the instructions:

2F 2G 2J 2K 2T 3D 2R

b If the plan provides welfare benefits, enter the applicable welfare feature codes from the List of Plan Characteristic Codes in the instructions:

9a Plan funding arrangement (check all that apply) (1) ☐ Insurance (2) ☐ Code section 412(e)(3) insurance contracts (3) ☒ Trust (4) ☐ General assets of the sponsor	9b Plan benefit arrangement (check all that apply) (1) ☐ Insurance (2) ☐ Code section 412(e)(3) insurance contracts (3) ☒ Trust (4) ☐ General assets of the sponsor
---	---

10 Check all applicable boxes in 10a and 10b to indicate which schedules are attached, and, where indicated, enter the number attached. (See instructions)

a Pension Schedules

- (1) ☒ **R** (Retirement Plan Information)
- (2) ☐ **MB** (Multiemployer Defined Benefit Plan and Certain Money Purchase Plan Actuarial Information) - signed by the plan actuary
- (3) ☐ **SB** (Single-Employer Defined Benefit Plan Actuarial Information) - signed by the plan actuary
- (4) ☐ **DCG** (Individual Plan Information) – Number Attached _____
- (5) ☐ **MEP** (Multiple-Employer Retirement Plan Information)

b General Schedules

- (1) ☒ **H** (Financial Information)
- (2) ☐ **I** (Financial Information – Small Plan)
- (3) ☐ **A** (Insurance Information) – Number Attached 0
- (4) ☒ **C** (Service Provider Information)
- (5) ☒ **D** (DFE/Participating Plan Information)
- (6) ☐ **G** (Financial Transaction Schedules)

Part III Form M-1 Compliance Information (to be completed by welfare benefit plans)

11a If the plan provides welfare benefits, was the plan subject to the Form M-1 filing requirements during the plan year? (See instructions and 29 CFR 2520.101-2.) ☐ Yes ☐ No

If "Yes" is checked, complete lines 11b and 11c.

11b Is the plan currently in compliance with the Form M-1 filing requirements? (See instructions and 29 CFR 2520.101-2.) ☐ Yes ☐ No

11c Enter the Receipt Confirmation Code for the 2025 Form M-1 annual report. If the plan was not required to file the 2025 Form M-1 annual report, enter the Receipt Confirmation Code for the most recent Form M-1 that was required to be filed under the Form M-1 filing requirements. (Failure to enter a valid Receipt Confirmation Code will subject the Form 5500 filing to rejection as incomplete.)

Receipt Confirmation Code _____

SCHEDULE C (Form 5500) Department of the Treasury Internal Revenue Service Department of Labor Employee Benefits Security Administration Pension Benefit Guaranty Corporation	Service Provider Information This schedule is required to be filed under section 104 of the Employee Retirement Income Security Act of 1974 (ERISA). ▶ File as an attachment to Form 5500.	OMB No. 1210-0110
		2025
		This Form is Open to Public Inspection.

For calendar plan year 2025 or fiscal plan year beginning 01/01/2025 and ending 12/31/2025		
A Name of plan AGIOS PHARMACEUTICALS 401(K) PLAN	B Three-digit plan number (PN) ▶	001
C Plan sponsor's name as shown on line 2a of Form 5500 AGIOS PHARMACEUTICALS	D Employer Identification Number (EIN) 26-0662915	

Part I	Service Provider Information (see instructions)
---------------	--

You must complete this Part, in accordance with the instructions, to report the information required for **each person** who received, directly or indirectly, \$5,000 or more in total compensation (i.e., money or anything else of monetary value) in connection with services rendered to the plan or the person's position with the plan during the plan year. If a person received **only** eligible indirect compensation for which the plan received the required disclosures, you are required to answer line 1 but are not required to include that person when completing the remainder of this Part.

1 Information on Persons Receiving Only Eligible Indirect Compensation

a Check "Yes" or "No" to indicate whether you are excluding a person from the remainder of this Part because they received only eligible indirect compensation for which the plan received the required disclosures (see instructions for definitions and conditions).. ☒ Yes ☐ No

b If you answered line 1a "Yes," enter the name and EIN or address of each person providing the required disclosures for the service providers who received only eligible indirect compensation. Complete as many entries as needed (see instructions).

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation
FIDELITY INVESTMENTS INSTITUTIONAL
04-2647786

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

(b) Enter name and EIN or address of person who provided you disclosures on eligible indirect compensation

2. Information on Other Service Providers Receiving Direct or Indirect Compensation. Except for those persons for whom you answered "Yes" to line 1a above, complete as many entries as needed to list each person receiving, directly or indirectly, \$5,000 or more in total compensation (i.e., money or anything else of value) in connection with services rendered to the plan or their position with the plan during the plan year. (See instructions).

(a) Enter name and EIN or address (see instructions)

FIDELITY INVESTMENTS INSTITUTIONAL

04-2647786

(b) Service Code(s)	(c) Relationship to employer, employee organization, or person known to be a party-in-interest	(d) Enter direct compensation paid by the plan. If none, enter -0-.	(e) Did service provider receive indirect compensation? (sources other than plan or plan sponsor)	(f) Did indirect compensation include eligible indirect compensation, for which the plan received the required disclosures?	(g) Enter total indirect compensation received by service provider excluding eligible indirect compensation for which you answered "Yes" to element (f). If none, enter -0-.	(h) Did the service provider give you a formula instead of an amount or estimated amount?
37 60 64 65	RECORDKEEPER	65424	Yes ☒ No ☐	Yes ☒ No ☐	0	Yes ☒ No ☐

(a) Enter name and EIN or address (see instructions)

(b) Service Code(s)	(c) Relationship to employer, employee organization, or person known to be a party-in-interest	(d) Enter direct compensation paid by the plan. If none, enter -0-.	(e) Did service provider receive indirect compensation? (sources other than plan or plan sponsor)	(f) Did indirect compensation include eligible indirect compensation, for which the plan received the required disclosures?	(g) Enter total indirect compensation received by service provider excluding eligible indirect compensation for which you answered "Yes" to element (f). If none, enter -0-.	(h) Did the service provider give you a formula instead of an amount or estimated amount?
			Yes ☐ No ☐	Yes ☐ No ☐		Yes ☐ No ☐

(a) Enter name and EIN or address (see instructions)

(b) Service Code(s)	(c) Relationship to employer, employee organization, or person known to be a party-in-interest	(d) Enter direct compensation paid by the plan. If none, enter -0-.	(e) Did service provider receive indirect compensation? (sources other than plan or plan sponsor)	(f) Did indirect compensation include eligible indirect compensation, for which the plan received the required disclosures?	(g) Enter total indirect compensation received by service provider excluding eligible indirect compensation for which you answered "Yes" to element (f). If none, enter -0-.	(h) Did the service provider give you a formula instead of an amount or estimated amount?
			Yes ☐ No ☐	Yes ☐ No ☐		Yes ☐ No ☐

Part I Service Provider Information (continued)

3. If you reported on line 2 receipt of indirect compensation, other than eligible indirect compensation, by a service provider, and the service provider is a fiduciary or provides contract administrator, consulting, custodial, investment advisory, investment management, broker, or recordkeeping services, answer the following questions for (a) each source from whom the service provider received \$1,000 or more in indirect compensation and (b) each source for whom the service provider gave you a formula used to determine the indirect compensation instead of an amount or estimated amount of the indirect compensation. Complete as many entries as needed to report the required information for each source.

(a) Enter service provider name as it appears on line 2	(b) Service Codes (see instructions)	(c) Enter amount of indirect compensation
FIDELITY INVESTMENTS INSTITUTIONAL	60	0

(d) Enter name and EIN (address) of source of indirect compensation	(e) Describe the indirect compensation, including any formula used to determine the service provider's eligibility for or the amount of the indirect compensation.
GQG PARTNERS EMERG MARKETS EQ INST 1 FREEDOM VALLEY DR OAKS, PA 19456	0.15%

(a) Enter service provider name as it appears on line 2	(b) Service Codes (see instructions)	(c) Enter amount of indirect compensation
FIDELITY INVESTMENTS INSTITUTIONAL	60	0

(d) Enter name and EIN (address) of source of indirect compensation	(e) Describe the indirect compensation, including any formula used to determine the service provider's eligibility for or the amount of the indirect compensation.
FPA NEW INCOME FUND 11601 WILSHIRE BLVD STE 1200 LOS ANGELES, CA 90025	0.10%

(a) Enter service provider name as it appears on line 2	(b) Service Codes (see instructions)	(c) Enter amount of indirect compensation
FIDELITY INVESTMENTS INSTITUTIONAL	60	0

(d) Enter name and EIN (address) of source of indirect compensation	(e) Describe the indirect compensation, including any formula used to determine the service provider's eligibility for or the amount of the indirect compensation.
JANUS HENDERSON GLOB TECH & INNOV 151 DETROIT ST. DENVER, CO 80206	0.35%

Part I Service Provider Information (continued)

3. If you reported on line 2 receipt of indirect compensation, other than eligible indirect compensation, by a service provider, and the service provider is a fiduciary or provides contract administrator, consulting, custodial, investment advisory, investment management, broker, or recordkeeping services, answer the following questions for (a) each source from whom the service provider received \$1,000 or more in indirect compensation and (b) each source for whom the service provider gave you a formula used to determine the indirect compensation instead of an amount or estimated amount of the indirect compensation. Complete as many entries as needed to report the required information for each source.

(a) Enter service provider name as it appears on line 2	(b) Service Codes (see instructions)	(c) Enter amount of indirect compensation
FIDELITY INVESTMENTS INSTITUTIONAL	60	0
(d) Enter name and EIN (address) of source of indirect compensation	(e) Describe the indirect compensation, including any formula used to determine the service provider's eligibility for or the amount of the indirect compensation.	
THORNBURG LTD TERM INCOME CLASS I 2300 NORTH RIDGETOP RD SANTA FE, NM 87506	0.15%	
(a) Enter service provider name as it appears on line 2	(b) Service Codes (see instructions)	(c) Enter amount of indirect compensation
(d) Enter name and EIN (address) of source of indirect compensation	(e) Describe the indirect compensation, including any formula used to determine the service provider's eligibility for or the amount of the indirect compensation.	
(a) Enter service provider name as it appears on line 2	(b) Service Codes (see instructions)	(c) Enter amount of indirect compensation
(d) Enter name and EIN (address) of source of indirect compensation	(e) Describe the indirect compensation, including any formula used to determine the service provider's eligibility for or the amount of the indirect compensation.	

Part II Service Providers Who Fail or Refuse to Provide Information

4 Provide, to the extent possible, the following information for each service provider who failed or refused to provide the information necessary to complete this Schedule.

(a) Enter name and EIN or address of service provider (see instructions)	(b) Nature of Service Code(s)	(c) Describe the information that the service provider failed or refused to provide
(a) Enter name and EIN or address of service provider (see instructions)	(b) Nature of Service Code(s)	(c) Describe the information that the service provider failed or refused to provide
(a) Enter name and EIN or address of service provider (see instructions)	(b) Nature of Service Code(s)	(c) Describe the information that the service provider failed or refused to provide
(a) Enter name and EIN or address of service provider (see instructions)	(b) Nature of Service Code(s)	(c) Describe the information that the service provider failed or refused to provide
(a) Enter name and EIN or address of service provider (see instructions)	(b) Nature of Service Code(s)	(c) Describe the information that the service provider failed or refused to provide
(a) Enter name and EIN or address of service provider (see instructions)	(b) Nature of Service Code(s)	(c) Describe the information that the service provider failed or refused to provide

Part III Termination Information on Accountants and Enrolled Actuaries (see instructions)
(complete as many entries as needed)

a Name:	b EIN:
c Position:	
d Address:	e Telephone:

Explanation:

a Name:	b EIN:
c Position:	
d Address:	e Telephone:

Explanation:

a Name:	b EIN:
c Position:	
d Address:	e Telephone:

Explanation:

a Name:	b EIN:
c Position:	
d Address:	e Telephone:

Explanation:

a Name:	b EIN:
c Position:	
d Address:	e Telephone:

Explanation:

SCHEDULE D (Form 5500) Department of the Treasury Internal Revenue Service Department of Labor Employee Benefits Security Administration	DFE/Participating Plan Information This schedule is required to be filed under section 104 of the Employee Retirement Income Security Act of 1974 (ERISA). ▶ File as an attachment to Form 5500.	OMB No. 1210-0110 2025 This Form is Open to Public Inspection.
---	---	---

For calendar plan year 2025 or fiscal plan year beginning 01/01/2025 and ending 12/31/2025		
A Name of plan AGIOS PHARMACEUTICALS 401(K) PLAN	B Three-digit plan number (PN) ▶	001
C Plan or DFE sponsor's name as shown on line 2a of Form 5500 AGIOS PHARMACEUTICALS	D Employer Identification Number (EIN) 26-0662915	

Part I	Information on interests in MTIAs, CCTs, PSAs, and 103-12 IEs (to be completed by plans and DFEs) (Complete as many entries as needed to report all interests in DFEs)
--------	---

a Name of MTIA, CCT, PSA, or 103-12 IE:	MIP CL 1
---	----------

b Name of sponsor of entity listed in (a):	FIDELITY MANAGEMENT TRUST COMPANY
--	-----------------------------------

c EIN-PN	04-3022712-024	d Entity code	C	e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)	383371
----------	----------------	---------------	---	--	--------

a Name of MTIA, CCT, PSA, or 103-12 IE:	
---	--

b Name of sponsor of entity listed in (a):	
--	--

c EIN-PN		d Entity code		e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)	
----------	--	---------------	--	--	--

a Name of MTIA, CCT, PSA, or 103-12 IE:	
---	--

b Name of sponsor of entity listed in (a):	
--	--

c EIN-PN		d Entity code		e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)	
----------	--	---------------	--	--	--

a Name of MTIA, CCT, PSA, or 103-12 IE:	
---	--

b Name of sponsor of entity listed in (a):	
--	--

c EIN-PN		d Entity code		e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)	
----------	--	---------------	--	--	--

a Name of MTIA, CCT, PSA, or 103-12 IE:	
---	--

b Name of sponsor of entity listed in (a):	
--	--

c EIN-PN		d Entity code		e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)	
----------	--	---------------	--	--	--

a Name of MTIA, CCT, PSA, or 103-12 IE:	
---	--

b Name of sponsor of entity listed in (a):	
--	--

c EIN-PN		d Entity code		e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)	
----------	--	---------------	--	--	--

a Name of MTIA, CCT, PSA, or 103-12 IE:	
---	--

b Name of sponsor of entity listed in (a):	
--	--

c EIN-PN		d Entity code		e Dollar value of interest in MTIA, CCT, PSA, or 103-12 IE at end of year (see instructions)	
----------	--	---------------	--	--	--

a Name of MTIA, CCT, PSA, or 103-12 IE:**b** Name of sponsor of entity listed in (a):**c** EIN-PN**d** Entity
code**e** Dollar value of interest in MTIA, CCT, PSA, or
103-12 IE at end of year (see instructions)**a** Name of MTIA, CCT, PSA, or 103-12 IE:**b** Name of sponsor of entity listed in (a):**c** EIN-PN**d** Entity
code**e** Dollar value of interest in MTIA, CCT, PSA, or
103-12 IE at end of year (see instructions)**a** Name of MTIA, CCT, PSA, or 103-12 IE:**b** Name of sponsor of entity listed in (a):**c** EIN-PN**d** Entity
code**e** Dollar value of interest in MTIA, CCT, PSA, or
103-12 IE at end of year (see instructions)**a** Name of MTIA, CCT, PSA, or 103-12 IE:**b** Name of sponsor of entity listed in (a):**c** EIN-PN**d** Entity
code**e** Dollar value of interest in MTIA, CCT, PSA, or
103-12 IE at end of year (see instructions)**a** Name of MTIA, CCT, PSA, or 103-12 IE:**b** Name of sponsor of entity listed in (a):**c** EIN-PN**d** Entity
code**e** Dollar value of interest in MTIA, CCT, PSA, or
103-12 IE at end of year (see instructions)**a** Name of MTIA, CCT, PSA, or 103-12 IE:**b** Name of sponsor of entity listed in (a):**c** EIN-PN**d** Entity
code**e** Dollar value of interest in MTIA, CCT, PSA, or
103-12 IE at end of year (see instructions)**a** Name of MTIA, CCT, PSA, or 103-12 IE:**b** Name of sponsor of entity listed in (a):**c** EIN-PN**d** Entity
code**e** Dollar value of interest in MTIA, CCT, PSA, or
103-12 IE at end of year (see instructions)**a** Name of MTIA, CCT, PSA, or 103-12 IE:**b** Name of sponsor of entity listed in (a):**c** EIN-PN**d** Entity
code**e** Dollar value of interest in MTIA, CCT, PSA, or
103-12 IE at end of year (see instructions)**a** Name of MTIA, CCT, PSA, or 103-12 IE:**b** Name of sponsor of entity listed in (a):**c** EIN-PN**d** Entity
code**e** Dollar value of interest in MTIA, CCT, PSA, or
103-12 IE at end of year (see instructions)**a** Name of MTIA, CCT, PSA, or 103-12 IE:**b** Name of sponsor of entity listed in (a):**c** EIN-PN**d** Entity
code**e** Dollar value of interest in MTIA, CCT, PSA, or
103-12 IE at end of year (see instructions)

Part II**Information on Participating Plans (to be completed by DFEs, other than DCGs)**

(Complete as many entries as needed to report all participating plans. DCGs must report each participating plan using Schedule DCG.)

a Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN**a** Plan name**b** Name of
plan sponsor**c** EIN-PN

SCHEDULE H (Form 5500) Department of the Treasury Department of the Treasury Internal Revenue Service Department of Labor Employee Benefits Security Administration Pension Benefit Guaranty Corporation	Financial Information This schedule is required to be filed under section 104 of the Employee Retirement Income Security Act of 1974 (ERISA), and section 6058(a) of the Internal Revenue Code (the Code). ▶ File as an attachment to Form 5500.	OMB No. 1210-0110 2025 This Form is Open to Public Inspection
	For calendar plan year 2025 or fiscal plan year beginning 01/01/2025 and ending 12/31/2025	
	A Name of plan AGIOS PHARMACEUTICALS 401(K) PLAN	B Three-digit plan number (PN) 001
C Plan sponsor's name as shown on line 2a of Form 5500 AGIOS PHARMACEUTICALS	D Employer Identification Number (EIN) 26-0662915	

Part I	Asset and Liability Statement		
1 Current value of plan assets and liabilities at the beginning and end of the plan year. Combine the value of plan assets held in more than one trust. Report the value of the plan's interest in a commingled fund containing the assets of more than one plan on a line-by-line basis unless the value is reportable on lines 1c(9) through 1c(14). Do not enter the value of that portion of an insurance contract which guarantees, during this plan year, to pay a specific dollar benefit at a future date. Round off amounts to the nearest dollar. MTIAs, CCTs, PSAs, and 103-12 IEs do not complete lines 1b(1), 1b(2), 1c(8), 1g, 1h, and 1i. CCTs, PSAs, and 103-12 IEs also do not complete lines 1d and 1e. See instructions.			
Assets		(a) Beginning of Year	(b) End of Year
a Total noninterest-bearing cash	1a	0	3025
b Receivables (less allowance for doubtful accounts):			
(1) Employer contributions	1b(1)	98632	0
(2) Participant contributions.....	1b(2)	257908	0
(3) Other	1b(3)	0	0
c General investments:			
(1) Interest-bearing cash (include money market accounts & certificates of deposit)	1c(1)	156275	1894299
(2) U.S. Government securities	1c(2)	0	0
(3) Corporate debt instruments (other than employer securities):			
(A) Preferred	1c(3)(A)	0	0
(B) All other	1c(3)(B)	0	0
(4) Corporate stocks (other than employer securities):			
(A) Preferred	1c(4)(A)	0	0
(B) Common	1c(4)(B)	58727	306023
(5) Partnership/joint venture interests	1c(5)	0	0
(6) Real estate (other than employer real property)	1c(6)	0	0
(7) Loans (other than to participants)	1c(7)	0	0
(8) Participant loans	1c(8)	616750	715388
(9) Value of interest in common/collective trusts	1c(9)	324649	383371
(10) Value of interest in pooled separate accounts	1c(10)	0	0
(11) Value of interest in master trust investment accounts	1c(11)	0	0
(12) Value of interest in 103-12 investment entities	1c(12)	0	0
(13) Value of interest in registered investment companies (e.g., mutual funds)	1c(13)	104685914	130874580
(14) Value of funds held in insurance company general account (unallocated contracts).....	1c(14)	0	0
(15) Other.....	1c(15)	0	0

1d Employer-related investments:		(a) Beginning of Year	(b) End of Year
(1) Employer securities	1d(1)	0	0
(2) Employer real property	1d(2)	0	0
1e Buildings and other property used in plan operation	1e	0	0
1f Total assets (add all amounts in lines 1a through 1e)	1f	106198855	134176686

Liabilities

1g Benefit claims payable	1g	0	0
1h Operating payables	1h	0	0
1i Acquisition indebtedness	1i	0	0
1j Other liabilities	1j	0	0
1k Total liabilities (add all amounts in lines 1g through 1j)	1k	0	0

Net Assets

1l Net assets (subtract line 1k from line 1f)	1l	106198855	134176686
--	-----------	-----------	-----------

Part II Income and Expense Statement

2 Plan income, expenses, and changes in net assets for the year. Include all income and expenses of the plan, including any trust(s) or separately maintained fund(s) and any payments/receipts to/from insurance carriers. Round off amounts to the nearest dollar. MTIAs, CCTs, PSAs, and 103-12 IEs do not complete lines 2a, 2b(1)(E), 2e, 2f, and 2g.

Income

		(a) Amount	(b) Total
a Contributions:			
(1) Received or receivable in cash from: (A) Employers	2a(1)(A)	4107221	
(B) Participants	2a(1)(B)	11252124	
(C) Others (including rollovers)	2a(1)(C)	4830416	
(2) Noncash contributions	2a(2)	0	20189761
(3) Total contributions. Add lines 2a(1)(A) , (B) , (C) , and line 2a(2)	2a(3)		
b Earnings on investments:			
(1) Interest:			
(A) Interest-bearing cash (including money market accounts and certificates of deposit)	2b(1)(A)	22233	
(B) U.S. Government securities	2b(1)(B)	0	
(C) Corporate debt instruments	2b(1)(C)	0	
(D) Loans (other than to participants)	2b(1)(D)	0	
(E) Participant loans	2b(1)(E)	48550	
(F) Other	2b(1)(F)	0	
(G) Total interest. Add lines 2b(1)(A) through (F)	2b(1)(G)		70783
(2) Dividends: (A) Preferred stock	2b(2)(A)	0	4062239
(B) Common stock	2b(2)(B)	2273	
(C) Registered investment company shares (e.g. mutual funds)	2b(2)(C)	4059966	
(D) Total dividends. Add lines 2b(2)(A) , (B) , and (C)	2b(2)(D)		4062239
(3) Rents	2b(3)		0
(4) Net gain (loss) on sale of assets: (A) Aggregate proceeds	2b(4)(A)	192188	-1098
(B) Aggregate carrying amount (see instructions)	2b(4)(B)	193286	
(C) Subtract line 2b(4)(B) from line 2b(4)(A) and enter result	2b(4)(C)		
(5) Unrealized appreciation (depreciation) of assets: (A) Real estate	2b(5)(A)	0	-1684
(B) Other	2b(5)(B)	-1684	
(C) Total unrealized appreciation of assets. Add lines 2b(5)(A) and (B)	2b(5)(C)		

		(a) Amount	(b) Total
(6) Net investment gain (loss) from common/collective trusts	2b(6)		9417
(7) Net investment gain (loss) from pooled separate accounts	2b(7)		0
(8) Net investment gain (loss) from master trust investment accounts	2b(8)		0
(9) Net investment gain (loss) from 103-12 investment entities	2b(9)		0
(10) Net investment gain (loss) from registered investment companies (e.g., mutual funds)	2b(10)		15511932
c Other income	2c		0
d Total income. Add all income amounts in column (b) and enter total	2d		39841350

Expenses

e Benefit payment and payments to provide benefits:			
(1) Directly to participants or beneficiaries, including direct rollovers	2e(1)	11795267	
(2) To insurance carriers for the provision of benefits	2e(2)	0	
(3) Other	2e(3)	0	
(4) Total benefit payments. Add lines 2e(1) through (3)	2e(4)		11795267
f Corrective distributions (see instructions)	2f		2828
g Certain deemed distributions of participant loans (see instructions)	2g		0
h Interest expense	2h		0
i Administrative expenses:			
(1) Salaries and allowances	2i(1)	0	
(2) Contract administrator fees	2i(2)	0	
(3) Recordkeeping fees	2i(3)	65424	
(4) IQPA audit fees	2i(4)	0	
(5) Investment advisory and investment management fees	2i(5)	0	
(6) Bank or trust company trustee/custodial fees	2i(6)	0	
(7) Actuarial fees	2i(7)	0	
(8) Legal fees	2i(8)	0	
(9) Valuation/appraisal fees	2i(9)	0	
(10) Other trustee fees and expenses	2i(10)	0	
(11) Other expenses	2i(11)	0	
(12) Total administrative expenses. Add lines 2i(1) through (11)	2i(12)		65424
j Total expenses. Add all expense amounts in column (b) and enter total	2j		11863519

Net Income and Reconciliation

k Net income (loss). Subtract line 2j from line 2d	2k		27977831
l Transfers of assets:			
(1) To this plan	2l(1)		0
(2) From this plan	2l(2)		0

Part III Accountant's Opinion

3 Complete lines 3a through 3c if the opinion of an independent qualified public accountant is attached to this Form 5500. Complete line 3d if an opinion is not attached.

a The attached opinion of an independent qualified public accountant for this plan is (see instructions):

(1) ☒ Unmodified (2) ☐ Qualified (3) ☐ Disclaimer (4) ☐ Adverse

b Check the appropriate box(es) to indicate whether the IQPA performed an ERISA section 103(a)(3)(C) audit. Check both boxes (1) and (2) if the audit was performed pursuant to both 29 CFR 2520.103-8 and 29 CFR 2520.103-12(d). Check box (3) if pursuant to neither.

(1) ☒ DOL Regulation 2520.103-8 (2) ☐ DOL Regulation 2520.103-12(d) (3) ☐ neither DOL Regulation 2520.103-8 nor DOL Regulation 2520.103-12(d).

c Enter the name and EIN of the accountant (or accounting firm) below:

(1) Name: **KAHN, LITWIN, RENZA & CO. LTD**

(2) EIN: **05-0409384**

d The opinion of an independent qualified public accountant is **not attached** as part of Schedule H because:

(1) ☐ This form is filed for a CCT, PSA, DCG or MTIA. (2) ☐ It will be attached to the next Form 5500 pursuant to 29 CFR 2520.104-50.

Part IV Compliance Questions

4 CCTs and PSAs do not complete Part IV. MTIAs, 103-12 IEs, and GIAs do not complete lines 4a, 4e, 4f, 4g, 4h, 4k, 4m, 4n, or 5. 103-12 IEs also do not complete lines 4j and 4l. MTIAs also do not complete line 4l. DCGs do not complete lines 4e, 4f, 4k, 4l, and 5, and DCGs generally complete the rest of Part IV collectively for all plans in the DCG, except as otherwise provided (see instructions).

During the plan year:

	Yes	No	Amount
a Was there a failure to transmit to the plan any participant contributions within the time period described in 29 CFR 2510.3-102? Continue to answer "Yes" for any prior year failures until fully corrected. (See instructions and DOL's Voluntary Fiduciary Correction Program.)	☒	☐	1682
b Were any loans by the plan or fixed income obligations due the plan in default as of the close of the plan year or classified during the year as uncollectible? Disregard participant loans secured by participant's account balance. (Attach Schedule G (Form 5500) Part I if "Yes" is checked.)	☐	☒	
c Were any leases to which the plan was a party in default or classified during the year as uncollectible? (Attach Schedule G (Form 5500) Part II if "Yes" is checked.)	☐	☒	
d Were there any nonexempt transactions with any party-in-interest? (Do not include transactions reported on line 4a. Attach Schedule G (Form 5500) Part III if "Yes" is checked.)	☐	☒	
e Was this plan covered by a fidelity bond?	☒	☐	3000000
f Did the plan have a loss, whether or not reimbursed by the plan's fidelity bond, that was caused by fraud or dishonesty?	☐	☒	
g Did the plan hold any assets whose current value was neither readily determinable on an established market nor set by an independent third party appraiser?	☐	☒	
h Did the plan receive any noncash contributions whose value was neither readily determinable on an established market nor set by an independent third party appraiser?	☐	☒	
i Did the plan have assets held for investment? (Attach schedule(s) of assets if "Yes" is checked, and see instructions for format requirements.)	☒	☐	
j Were any plan transactions or series of transactions in excess of 5% of the current value of plan assets? (Attach schedule of transactions if "Yes" is checked and see instructions for format requirements.)	☐	☒	
k Were all the plan assets either distributed to participants or beneficiaries, transferred to another plan, or brought under the control of the PBGC?	☐	☒	
l Has the plan failed to provide any benefit when due under the plan?	☐	☒	
m If this is an individual account plan, was there a blackout period? (See instructions and 29 CFR 2520.101-3.)	☐	☒	
n If 4m was answered "Yes," check the "Yes" box if you either provided the required notice or one of the exceptions to providing the notice applied under 29 CFR 2520.101-3.	☐	☐	

5a Has a resolution to terminate the plan been adopted during the plan year or any prior plan year? ☐ Yes ☒ No
If "Yes," enter the amount of any plan assets that reverted to the employer this year _____.

5b If, during this plan year, any assets or liabilities were transferred from this plan to another plan(s), identify the plan(s) to which assets or liabilities were transferred. (See instructions.)

5b(1) Name of plan(s)	5b(2) EIN(s)	5b(3) PN(s)

5c Was the plan a defined benefit plan covered under the PBGC insurance program at any time during this plan year? (See ERISA section 4021 and instructions.) ☐ Yes ☐ No ☐ Not determined

If "Yes" is checked, enter the My PAA confirmation number from the PBGC premium filing for this plan year _____.

SCHEDULE R (Form 5500) Department of the Treasury Internal Revenue Service Department of Labor Employee Benefits Security Administration Pension Benefit Guaranty Corporation	Retirement Plan Information This schedule is required to be filed under sections 104 and 4065 of the Employee Retirement Income Security Act of 1974 (ERISA) and section 6058(a) of the Internal Revenue Code (the Code). ▶ File as an attachment to Form 5500.	OMB No. 1210-0110 2025 This Form is Open to Public Inspection.
For calendar plan year 2025 or fiscal plan year beginning 01/01/2025 and ending 12/31/2025		
A Name of plan AGIOS PHARMACEUTICALS 401(K) PLAN		B Three-digit plan number (PN) ▶ 001
C Plan sponsor's name as shown on line 2a of Form 5500 AGIOS PHARMACEUTICALS		D Employer Identification Number (EIN) 26-0662915
Part I	Distributions	
All references to distributions relate only to payments of benefits during the plan year.		
1 Total value of distributions paid in property other than in cash or the forms of property specified in the instructions.....		1
2 Enter the EIN(s) of payor(s) who paid benefits on behalf of the plan to participants or beneficiaries during the year (if more than two, enter EINs of the two payors who paid the greatest dollar amounts of benefits): EIN(s): 04-6568107		
Profit-sharing plans, ESOPs, and stock bonus plans, skip line 3.		
3 Number of participants (living or deceased) whose benefits were distributed in a single sum, during the plan year.....		3
Part II	Funding Information (If the plan is not subject to the minimum funding requirements of section 412 of the Internal Revenue Code or ERISA section 302, skip this Part.)	
4 Is the plan administrator making an election under Code section 412(d)(2) or ERISA section 302(d)(2)? ☐ Yes ☐ No ☐ N/A		
If the plan is a defined benefit plan, go to line 8.		
5 If a waiver of the minimum funding standard for a prior year is being amortized in this plan year, see instructions and enter the date of the ruling letter granting the waiver. Date: Month _____ Day _____ Year _____		
If you completed line 5, complete lines 3, 9, and 10 of Schedule MB and do not complete the remainder of this schedule.		
6 a Enter the minimum required contribution for this plan year (include any prior year accumulated funding deficiency not waived)		6a
b Enter the amount contributed by the employer to the plan for this plan year		6b
c Subtract the amount in line 6b from the amount in line 6a. Enter the result (enter a minus sign to the left of a negative amount).....		6c
If you completed line 6c, skip lines 8 and 9.		
7 Will the minimum funding amount reported on line 6c be met by the funding deadline? ☐ Yes ☐ No ☐ N/A		
8 If a change in actuarial cost method was made for this plan year pursuant to a revenue procedure or other authority providing automatic approval for the change or a class ruling letter, does the plan sponsor or plan administrator agree with the change? ☐ Yes ☐ No ☐ N/A		
Part III	Amendments	
9 If this is a defined benefit pension plan, were any amendments adopted during this plan year that increased or decreased the value of benefits? If yes, check the appropriate box. If no, check the "No" box..... ☐ Increase ☐ Decrease ☐ Both ☐ No		
Part IV	ESOPs (see instructions). If this is not a plan described under section 409(a) or 4975(e)(7) of the Internal Revenue Code, skip this Part.	
10 Were unallocated employer securities or proceeds from the sale of unallocated securities used to repay any exempt loan? ☐ Yes ☐ No		
11 a Does the ESOP hold any preferred stock? ☐ Yes ☐ No		
b If the ESOP has an outstanding exempt loan with the employer as lender, is such loan part of a "back-to-back" loan? (See instructions for definition of "back-to-back" loan.) ☐ Yes ☐ No		
12 Does the ESOP hold any stock that is not readily tradable on an established securities market? ☐ Yes ☐ No		
For Paperwork Reduction Act Notice, see the Instructions for Form 5500.		
Schedule R (Form 5500) 2025 v. 250312		

Part V Additional Information for Multiemployer Defined Benefit Pension Plans

13 Enter the following information for each employer that (1) contributed more than 5% of total contributions to the plan during the plan year or (2) was one of the top-ten highest contributors (measured in dollars). See instructions. *Complete as many entries as needed to report all applicable employers.*

a Name of contributing employer

b EIN

c Dollar amount contributed by employer

d Date collective bargaining agreement expires (If employer contributes under more than one collective bargaining agreement, check box ☐ and see instructions regarding required attachment. Otherwise, enter the applicable date.) Month _____ Day _____ Year _____

e Contribution rate information (If more than one rate applies, check this box ☐ and see instructions regarding required attachment. Otherwise, complete lines 13e(1) and 13e(2).)

(1) Contribution rate (in dollars and cents) _____

(2) Base unit measure: ☐ Hourly ☐ Weekly ☐ Unit of production ☐ Other (specify): _____

a Name of contributing employer

b EIN

c Dollar amount contributed by employer

d Date collective bargaining agreement expires (If employer contributes under more than one collective bargaining agreement, check box ☐ and see instructions regarding required attachment. Otherwise, enter the applicable date.) Month _____ Day _____ Year _____

e Contribution rate information (If more than one rate applies, check this box ☐ and see instructions regarding required attachment. Otherwise, complete lines 13e(1) and 13e(2).)

(1) Contribution rate (in dollars and cents) _____

(2) Base unit measure: ☐ Hourly ☐ Weekly ☐ Unit of production ☐ Other (specify): _____

a Name of contributing employer

b EIN

c Dollar amount contributed by employer

d Date collective bargaining agreement expires (If employer contributes under more than one collective bargaining agreement, check box ☐ and see instructions regarding required attachment. Otherwise, enter the applicable date.) Month _____ Day _____ Year _____

e Contribution rate information (If more than one rate applies, check this box ☐ and see instructions regarding required attachment. Otherwise, complete lines 13e(1) and 13e(2).)

(1) Contribution rate (in dollars and cents) _____

(2) Base unit measure: ☐ Hourly ☐ Weekly ☐ Unit of production ☐ Other (specify): _____

a Name of contributing employer

b EIN

c Dollar amount contributed by employer

d Date collective bargaining agreement expires (If employer contributes under more than one collective bargaining agreement, check box ☐ and see instructions regarding required attachment. Otherwise, enter the applicable date.) Month _____ Day _____ Year _____

e Contribution rate information (If more than one rate applies, check this box ☐ and see instructions regarding required attachment. Otherwise, complete lines 13e(1) and 13e(2).)

(1) Contribution rate (in dollars and cents) _____

(2) Base unit measure: ☐ Hourly ☐ Weekly ☐ Unit of production ☐ Other (specify): _____

a Name of contributing employer

b EIN

c Dollar amount contributed by employer

d Date collective bargaining agreement expires (If employer contributes under more than one collective bargaining agreement, check box ☐ and see instructions regarding required attachment. Otherwise, enter the applicable date.) Month _____ Day _____ Year _____

e Contribution rate information (If more than one rate applies, check this box ☐ and see instructions regarding required attachment. Otherwise, complete lines 13e(1) and 13e(2).)

(1) Contribution rate (in dollars and cents) _____

(2) Base unit measure: ☐ Hourly ☐ Weekly ☐ Unit of production ☐ Other (specify): _____

a Name of contributing employer

b EIN

c Dollar amount contributed by employer

d Date collective bargaining agreement expires (If employer contributes under more than one collective bargaining agreement, check box ☐ and see instructions regarding required attachment. Otherwise, enter the applicable date.) Month _____ Day _____ Year _____

e Contribution rate information (If more than one rate applies, check this box ☐ and see instructions regarding required attachment. Otherwise, complete lines 13e(1) and 13e(2).)

(1) Contribution rate (in dollars and cents) _____

(2) Base unit measure: ☐ Hourly ☐ Weekly ☐ Unit of production ☐ Other (specify): _____

14 Enter the number of deferred vested and retired participants (inactive participants), as of the beginning of the plan year, whose contributing employer is no longer making contributions to the plan for:

a The current plan year. Check the box to indicate the counting method used to determine the number of inactive participants: ☐ last contributing employer ☐ alternative ☐ reasonable approximation (see instructions for required attachment).....

14a

b The plan year immediately preceding the current plan year. ☐ Check the box if the number reported is a change from what was previously reported (see instructions for required attachment).....

14b

c The second preceding plan year. ☐ Check the box if the number reported is a change from what was previously reported (see instructions for required attachment).....

14c

15 Enter the ratio of the number of participants under the plan on whose behalf no employer had an obligation to make an employer contribution during the current plan year to:

a The corresponding number for the plan year immediately preceding the current plan year.....

15a

b The corresponding number for the second preceding plan year.....

15b

16 Information with respect to any employers who withdrew from the plan during the preceding plan year:

a Enter the number of employers who withdrew during the preceding plan year.....

16a

b If line 16a is greater than 0, enter the aggregate amount of withdrawal liability assessed or estimated to be assessed against such withdrawn employers.....

16b

17 If assets and liabilities from another plan have been transferred to or merged with this plan during the plan year, check box and see instructions regarding supplemental information to be included as an attachment..... ☐

Part VI Additional Information for Single-Employer and Multiemployer Defined Benefit Pension Plans

18 If any liabilities to participants or their beneficiaries under the plan as of the end of the plan year consist (in whole or in part) of liabilities to such participants and beneficiaries under two or more pension plans as of immediately before such plan year, check box and see instructions regarding supplemental information to be included as an attachment..... ☐

19 If the total number of participants is 1,000 or more, complete lines (a) and (b):

a Enter the percentage of plan assets held as:

Public Equity: _____% Private Equity: _____% Investment-Grade Debt and Interest Rate Hedging Assets: _____%

High-Yield Debt: _____% Real Assets: _____% Cash or Cash Equivalents: _____% Other: _____%

b Provide the average duration of the Investment-Grade Debt and Interest Rate Hedging Assets:

☐ 0-5 years ☐ 5-10 years ☐ 10-15 years ☐ 15 years or more

20 PBGC missed contribution reporting requirements. If this is a multiemployer plan or a single-employer plan that is not covered by PBGC, skip line 20.

a Is the amount of unpaid minimum required contributions for all years from Schedule SB (Form 5500) line 40 greater than zero? ☐ Yes ☐ No

b If line 20a is "Yes," has PBGC been notified as required by ERISA sections 4043(c)(5) and/or 303(k)(4)? Check the applicable box:

☐ Yes.

☐ No. Reporting was waived under 29 CFR 4043.25(c)(2) because contributions equal to or exceeding the unpaid minimum required contribution were made by the 30th day after the due date.

☐ No. The 30-day period referenced in 29 CFR 4043.25(c)(2) has not yet ended, and the sponsor intends to make a contribution equal to or exceeding the unpaid minimum required contribution by the 30th day after the due date.

☐ No. Other. Provide explanation.....

Part VII IRS Compliance Questions

21a Does the plan satisfy the coverage and nondiscrimination tests of Code sections 410(b) and 401(a)(4) by combining this plan with any other plans under the permissive aggregation rules? ☐ Yes ☒ No

21b If this is a Code section 401(k) plan, check all boxes that apply to indicate how the plan is intended to satisfy the nondiscrimination requirements for employee deferrals and employer matching contributions (as applicable) under Code sections 401(k)(3) and 401(m)(2).

☐ Design-based safe harbor method

☐ "Prior year" ADP test

☒ "Current year" ADP test

☐ N/A

22 If the plan sponsor is an adopter of a pre-approved plan that received a favorable IRS Opinion Letter, enter the date of the Opinion Letter 06 / 30 / 2020 (MM/DD/YYYY) and the Opinion Letter serial number Q702438A.

AGIOS PHARMACEUTICALS 401(K) PLAN

**Financial Statements
and Supplemental Schedules**

December 31, 2025 and 2024

(With Independent Auditors' Report Thereon)

AGIOS PHARMACEUTICALS 401(K) PLAN

FINANCIAL STATEMENTS AND SUPPLEMENTAL SCHEDULES

December 31, 2025 and 2024

	<u>Page</u>
INDEPENDENT AUDITORS' REPORT	1
FINANCIAL STATEMENTS:	
Statements of Net Assets Available for Plan Benefits	5
Statement of Changes in Net Assets Available for Plan Benefits	6
Notes to the Financial Statements	7
SUPPLEMENTAL SCHEDULES (Note A):	
Schedule of Delinquent Participant Contributions	16
Schedule of Assets (Held at End of Year)	17

Note A: Schedules not included with this supplemental data have been omitted because they are not applicable.

INDEPENDENT AUDITORS' REPORT

To the Plan Administrator of the
Agios Pharmaceuticals 401(k) Plan:

Scope and Nature of the ERISA Section 103(a)(3)(C) Audit

We have performed audits of the financial statements of the Agios Pharmaceuticals 401(k) Plan (the Plan), an employee benefit plan subject to the Employee Retirement Income Security Act of 1974 (ERISA), as permitted by ERISA Section 103(a)(3)(C) (ERISA Section 103(a)(3)(C) audit). The financial statements comprise the Statements of Net Assets Available for Plan Benefits as of December 31, 2025 and 2024, and the related Statement of Changes in Net Assets Available for Plan Benefits for the year ended December 31, 2025, and the related notes to the financial statements.

Management, having determined it is permissible in the circumstances, has elected to have the audits of the Plan's financial statements performed in accordance with ERISA Section 103(a)(3)(C) pursuant to 29 CFR 2520.103-8 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA. As permitted by ERISA Section 103(a)(3)(C), our audits need not extend to any statements or information related to assets held for investment of the Plan (investment information) by a bank or similar institution or insurance carrier that is regulated, supervised, and subject to periodic examination by a state or federal agency, provided that the statements or information regarding assets so held are prepared and certified to by the bank or similar institution or insurance carrier in accordance with 29 CFR 2520.103-5 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA (qualified institution).

Management has obtained certifications from a qualified institution as of December 31, 2025 and 2024 and for the year ended December 31, 2025, stating that the certified investment information, as described in Note 6 to the financial statements, is complete and accurate.

Opinion

In our opinion, based on our audits and on the procedures performed as described in the Auditors' Responsibilities for the Audit of the Financial Statements section:

- the amounts and disclosures in the financial statements referred to above, other than those agreed to or derived from the certified investment information, are presented fairly, in all material respects, in accordance with accounting principles generally accepted in the United States of America.
- the information in the financial statements referred to above related to assets held by and certified to by a qualified institution agrees to, or is derived from, in all material respects, the information prepared and certified by an institution that management determined meets the requirements of ERISA Section 103(a)(3)(C).

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Plan and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our ERISA Section 103(a)(3)(C) audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error. Management's election of the ERISA Section 103(a)(3)(C) audit does not affect management's responsibility for the financial statements.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Plan's ability to continue as a going concern for one year after the date the financial statements are available to be issued.

Management is also responsible for maintaining a current plan instrument, including all plan amendments; administering the Plan; and determining that the Plan's transactions that are presented and disclosed in the financial statements are in conformity with the Plan's provisions, including maintaining sufficient records with respect to each of the participants, to determine the benefits due or which may become due to such participants.

Auditors' Responsibilities for the Audit of the Financial Statements

Except as described in the Scope and Nature of the ERISA Section 103(a)(3)(C) Audit section of our report, our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Plan's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Plan's ability to continue as a going concern for a reasonable period of time.

Our audits did not extend to the certified investment information, except for obtaining and reading the certification, comparing the certified investment information with the related information presented and disclosed in the financial statements, and reading the disclosures relating to the certified investment information to assess whether they are in accordance with the presentation and disclosure requirements of accounting principles generally accepted in the United States of America.

Accordingly, the objective of an ERISA Section 103(a)(3)(C) audit is not to express an opinion about whether the financial statements as a whole are presented fairly, in all material respects, in accordance with accounting principles generally accepted in the United States of America.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Supplemental Schedules Required by ERISA

The supplemental Schedule of Delinquent Participant Contributions for the year ended December 31, 2025 and Schedule of Assets (Held at End of Year) as of December 31, 2025 are presented for purposes of additional analysis and are not a required part of the financial statements but are supplemental information required by the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information included in the supplemental schedules, other than that agreed to or derived from the certified investment information, has been subjected to auditing procedures applied in the audits of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with GAAS. For information included in the supplemental schedules that agreed to or is derived from the certified investment information, we compared such information to the related certified investment information.

In forming our opinion on the supplemental schedules, we evaluated whether the supplemental schedules, other than the information agreed to or derived from the certified investment information, including its form and content, are presented in conformity with the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA.

In our opinion:

- the form and content of the supplemental schedules, other than the information in the supplemental schedules that agreed to or is derived from the certified investment information, are presented, in all material respects, in conformity with the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA.
- the information in the supplemental schedules related to assets held by and certified to by a qualified institution agrees to, or is derived from, in all material respects, the information prepared and certified by an institution that management determined meets the requirements of ERISA Section 103(a)(3)(C).

Kahn, Litwin, Renya & Co., Ltd.

July 16, 2026

AGIOS PHARMACEUTICALS 401(K) PLAN
STATEMENTS OF NET ASSETS AVAILABLE FOR PLAN BENEFITS
December 31, 2025 and 2024



	<u>2025</u>	<u>2024</u>
Assets		
Investments, at fair value:		
Cash and cash equivalents	\$ 1,122,584	\$ 43,592
Mutual funds	130,052,069	103,813,590
Common collective trusts	383,371	324,649
Self-directed brokerage accounts	1,903,274	1,043,734
	<u>133,461,298</u>	<u>105,225,565</u>
Receivables:		
Participant contributions	-	257,908
Company contributions	-	98,632
Participant notes	715,388	616,750
	<u>715,388</u>	<u>973,290</u>
Net Assets Available for Plan Benefits	<u>\$ 134,176,686</u>	<u>\$ 106,198,855</u>

AGIOS PHARMACEUTICALS 401(K) PLAN
STATEMENT OF CHANGES IN NET ASSETS AVAILABLE FOR PLAN BENEFITS
Year Ended December 31, 2025



Additions to net assets attributed to:

Investment income:

Interest and dividends	\$ 4,034,869
Net appreciation in fair value of investments	15,568,170
	<u>19,603,039</u>

Interest income from participant notes receivable	<u>48,550</u>
---	---------------

Contributions:

Participant	11,252,124
Company	4,107,221
Rollovers	4,830,416
	<u>20,189,761</u>

Total additions	<u>39,841,350</u>
------------------------	--------------------------

Deductions from net assets attributed to:

Benefits paid to participants	11,798,095
Administrative expenses	65,424
Total deductions	<u>11,863,519</u>

Net increase	27,977,831
---------------------	-------------------

Net Assets Available for Plan Benefits:

Beginning of year	<u>106,198,855</u>
End of year	<u>\$ 134,176,686</u>

**AGIOS PHARMACEUTICALS 401(K) PLAN
NOTES TO THE FINANCIAL STATEMENTS
December 31, 2025 and 2024**



1. Description of the Plan

The following description of the Agios Pharmaceuticals 401(k) Plan (the Plan) is intended to provide only general information regarding the Plan. Participants should refer to the Plan Document for a more complete description of the Plan's provisions.

General

The Plan is a defined contribution plan established to provide employees of Agios Pharmaceuticals (the Company or Employer) with retirement benefits in accordance with Sections 401(a) and 401(k) of the Internal Revenue Code (IRC). The Plan covers all employees of the Company upon attaining the age of 21, except those covered by a collective bargaining agreement, leased employees, non-resident aliens, temporary or contract employees, and interns. Eligible participants can enroll in the Plan at the beginning of the next payroll period following their date of hire. The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974 (ERISA).

The Company is also the administrator of the Plan. As administrator, the Company has exclusive authority and responsibility for all matters in connection with the operation and administration of the Plan. Fidelity Management Trust Company (Fidelity) is the appointed trustee of the Plan and acts at the direction of the Plan Administrator.

Contributions

Participants may make voluntary contributions through salary reductions from 1% to 75% of their eligible annual pre-tax compensation, as defined by the Plan document, limited to the maximum amounts allowed under the provisions of the IRC (\$23,500 in 2025). Further, participants who are 50 years of age or older as of December 31, 2025, may contribute an additional "catch-up" contribution (\$7,500 in 2025). The Plan also allows rollover contributions from other qualified plans, as defined in the Plan Document. Participants direct the investment of their contributions into various investment options offered by the Plan. The Plan currently offers various mutual funds, brokerage funds, and common collective trusts as investment options for participants.

Effective January 1, 2025, the Plan adopted a provision of the Setting Every Community Up for Retirement Enhancement Act of 2022 (SECURE) Act 2.0 allowing certain eligible participants to make increased catch-up elective deferrals, referred to as "super catch-up" contributions. Under this provision, the maximum catch-up deferral amount for participants between the ages of 60 and 63 increased from \$7,500 to \$11,250.

The Plan also allows participants to defer funds into a "Roth 401(k) deferral." These deferrals are subject to federal income taxes, and the maximum allowable combined contributions of the Roth 401(k) and the pre-tax deferrals is \$23,500 (\$31,000 or \$34,750 with additional "catch-up" and "super catch-up" contributions, respectively). In addition, participants can also make voluntary, non-deductible, after-tax contributions limited to 75% of eligible compensation.

**AGIOS PHARMACEUTICALS 401(K) PLAN
NOTES TO THE FINANCIAL STATEMENTS
December 31, 2025 and 2024**



The Company may make discretionary matching contributions. For the year ended December 31, 2025, the Company matched 100% of employee pre-tax and Roth 401(k) contributions up to 4% of compensation. Participant voluntary, non-deductible, after-tax contributions are not eligible for matching contributions. For the plan year ended December 31, 2025, the Company made matching contributions of \$4,107,221.

Participant Accounts

Each participant's account is credited with the participant's contributions, the Company's matching contributions and their allocation of Plan earnings/losses and any expenses incurred. Allocations are based on participant compensation or individual account balances, as defined. The benefit to which a participant is entitled is the benefit that can be provided from the participant's vested account.

Vesting

Participants are immediately vested in their voluntary contributions, rollover contributions, discretionary matching contributions, and earnings thereon.

Participant Notes Receivable

Participants may borrow from their account a minimum of \$1,000 up to a maximum equal to the lesser of \$50,000 within a 12-month period or 50% of their vested account balance. A participant can only have one loan outstanding at any time. Terms range from 1 to 5 years, or up to 10 years for the purchase of a primary residence. The notes are secured by the vested balance in the participant's account and bear interest at a rate determined reasonable by the Plan Administrator as defined in the Plan document. The interest rate is fixed for the term of the loan. Principal and interest is paid ratably through payroll deductions.

The Plan allows terminated participants with an outstanding loan to continue making payments after termination in accordance with the promissory note.

Forfeitures

As of December 31, 2025 and 2024, forfeited non-vested accounts totaled \$11,863 and \$9,575, respectively. These accounts may be used to pay administrative expenses or reduce future Company contributions. For the year ended December 31, 2025, \$50 of the forfeiture balance was used to pay administrative expenses.

Payment of Benefits

The Plan allows for in-service distributions of the participant's vested accounts upon reaching the age of 59 ½ or due to hardship, as defined by the Plan. In-service withdrawals are also permitted for Rollover and Roth Rollover account balances at any time. The Plan also provides for mandatory distributions to participants upon reaching the age of 73. Upon retirement, death, disability or termination of employment, a participant (or participant's beneficiary in the event of death) will be entitled to 100% of their vested account balance, payable in a single lump-sum distribution.

**AGIOS PHARMACEUTICALS 401(K) PLAN
NOTES TO THE FINANCIAL STATEMENTS
December 31, 2025 and 2024**



If a participant's vested balance is equal to or less than \$1,000, the participant will receive an immediate cash-out of their vested account balance, and the non-vested portion shall be treated as a forfeiture. If a participant's vested balance exceeds \$1,000 and is equal to or less than \$7,000, the amount will be rolled over to an individual retirement plan designated by the trustee, unless otherwise directed by the participant.

Hardship Withdrawals

Hardship withdrawals are allowed under the provisions of the Plan and cannot exceed the amount required to meet the immediate financial need created by the hardship.

2. Summary of Significant Accounting Policies

Basis of Accounting

The Plan's financial statements have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America.

Valuation of Investments and Income Recognition

The Plan's investments are reported at fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (Note 3). The Plan invests in the Fidelity Managed Income Portfolio (MIP), which is a common collective trust fund. The Plan's interest in the MIP is valued at the net asset value (NAV) practical expedient of the underlying investments reported by the issuer of the common collective trust at year-end. The Plan Administrator determines the Plan's valuation policies utilizing information provided by the investment advisors and trustee.

Purchases and sales of securities are recorded on a trade-date basis. Dividends are recorded on the ex-dividend date. Interest income is recorded on the accrual basis. Net appreciation or depreciation includes the Plan's gains and losses on investments bought and sold, as well as held during the year.

Participant Notes Receivable

Participant notes receivable are measured at their unpaid principal balances plus any accrued but unpaid interest and are secured by the balance in the respective participant's account.

Related fees are recorded as administrative expenses and are expensed when they are incurred. Interest income on participant notes receivable is recorded when it is earned. A receivable is considered past due if payment has not been received within the stated terms. Delinquent participant notes receivable are reclassified as distributions based on terms of the Plan Document.

Contributions

Participant and Company matching contributions are recorded bi-weekly or semi-monthly when the Company remits the contributions for investment into the Plan.

**AGIOS PHARMACEUTICALS 401(K) PLAN
NOTES TO THE FINANCIAL STATEMENTS
December 31, 2025 and 2024**



Payment of Benefits

Benefits are recorded when paid to participants or their designated beneficiaries.

Administrative Expenses

Certain administrative expenses of the Plan are paid by the Company, unless the Company directs that such expenses be paid by the Plan. Expenses that are paid by the Company are excluded from these financial statements. Investment management and recordkeeping fees, if applicable, are paid by the Plan through revenue sharing as a reduction of investment income (net appreciation or depreciation) from the related investment fund. Participant notes receivable set-up and administration fees are charged directly against a participant's account on a pro-rata basis from all of the funds in which the respective participant is invested at the time the fees are taken and are included in administrative expenses.

Estimates

The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires the Plan Administrator to make estimates and assumptions that affect certain reported amounts of assets, liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported changes in net assets. Accordingly, actual results may differ from those estimates.

Risks and Uncertainties

The Plan provides for various investment options with a variety of investment objectives. Investment securities are exposed to various risks such as interest rate risk, market risk and credit risk. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect participants' account balances and the amounts reported in the Statements of Net Assets Available for Plan Benefits.

The Plan invested in three and four mutual funds that accounted for approximately 33% and 44% of total Plan investments as of December 31, 2025 and 2024, respectively.

Financial Instruments with a Concentration of Credit Risk

The Plan's investments are held by a single trustee. The Plan's exposure to credit risk is associated with the outside entity's non-performance of their fiduciary responsibilities relating to these amounts as specified in the agreements. Benefits provided by the Plan are not insured or guaranteed by the Pension Benefit Guaranty Corporation.

Subsequent Events

Management has evaluated subsequent events through July 16, 2026, which is the date these financial statements were available to be issued.

AGIOS PHARMACEUTICALS 401(K) PLAN
NOTES TO THE FINANCIAL STATEMENTS
December 31, 2025 and 2024



3. Fair Value Measurements

The framework for measuring fair value provides a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives highest priority to unadjusted quoted prices in active markets for identical assets (level 1) and the lowest priority to unobservable inputs (level 3).

The three levels of the fair value hierarchy and inputs to the valuation methodologies are described as follows:

Level 1 inputs are unadjusted quoted prices in active markets for identical assets the Plan has the ability to access.

Level 2 inputs are other than quoted prices in active markets that are observable either directly or indirectly for the asset. Such inputs are derived principally from or corroborated by observable market data for similar assets by correlation or other means, over substantially the full contractual term of the asset, if applicable.

Level 3 inputs are unobservable and significant to the fair value measurement. Such inputs generally rely on the Plan's own assumptions about the assumptions that market participants would use in pricing the asset.

The asset's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques maximize the use of relevant observable inputs and minimize the use of unobservable inputs.

The following is a description of the valuation methodologies used for assets measured at fair value on a recurring basis.

Cash and Cash Equivalents: The carrying amounts of cash and cash equivalents are valued at deposit amount plus accrued interest, as determined according to stated terms.

Mutual Funds: Valued at the daily closing price as reported by the fund. Mutual funds held by the Plan are open-end mutual funds that are registered with the Securities and Exchange Commission. These funds are required to publish their daily NAV and to transact at that price. The mutual funds held by the Plan are deemed to be actively traded.

Self-directed Brokerage Accounts: Valued at the closing price reported on the active market on which the individual securities are traded. This account consists of cash, common stock, mutual funds and federal bonds.

AGIOS PHARMACEUTICALS 401(K) PLAN
NOTES TO THE FINANCIAL STATEMENTS
December 31, 2025 and 2024



Common Collective Trust: The Plan invests in the Fidelity Managed Income Portfolio, an investment vehicle that invests in benefit-responsive investment contracts, fixed income securities and money market funds. Units held are valued at NAV. The NAV, as provided by Fidelity, is used as a practical expedient to estimate fair value. The NAV is based on the fair value of the underlying investments held by the fund less its liabilities.

This practical expedient is not used when it is determined to be probable that the fund will sell the investment for an amount different than the reported NAV. Unit values are determined by dividing the fund's net assets at fair value by its units outstanding at the valuation dates. Participant transactions (purchases and sales) may occur daily. There are no unfunded commitments or redemption restrictions for the Plan, however, there is up to a 12-month redemption for this investment at the Plan level.

As of December 31, 2025, the Plan's investments are reported at fair value in the accompanying Statements of Net Assets Available for Plan Benefits as follows:

	Level 1	Total
Cash and cash equivalents	\$ 1,122,584	\$ 1,122,584
Mutual funds	130,052,069	130,052,069
Self-directed brokerage accounts	1,903,274	1,903,274
Total assets in the fair value hierarchy	<u>133,077,927</u>	<u>133,077,927</u>
Common collective trust measured at NAV (a)		<u>383,371</u>
Total investments at fair value		<u><u>\$ 133,461,298</u></u>

AGIOS PHARMACEUTICALS 401(K) PLAN
NOTES TO THE FINANCIAL STATEMENTS
December 31, 2025 and 2024



As of December 31, 2024, the Plan's investments are reported at fair value in the accompanying Statements of Net Assets Available for Plan Benefits as follows:

	Level 1	Total
Cash and cash equivalents	\$ 43,592	\$ 43,592
Mutual funds	103,813,590	103,813,590
Self-directed brokerage accounts	1,043,734	1,043,734
Total assets in the fair value hierarchy	<u>104,900,916</u>	<u>104,900,916</u>
Common collective trust measured at NAV (a)		<u>324,649</u>
Total investments at fair value		<u><u>\$ 105,225,565</u></u>

(a) In accordance with Subtopic 820-10, the common collective trust funds were measured at NAV per share (or its equivalent) and have not been classified in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value to the line items presented in the Statements of Net Assets Available for Plan Benefits.

4. Plan Termination

The Company expects to continue the Plan indefinitely. However, the Company reserves the right to amend the Plan or contributions thereto, at any time and in any manner that it deems advisable, provided that no amendment shall have the effect of diverting Plan assets for purposes other than for the exclusive benefit of the Plan participants and any Plan termination would be subject to the provisions of ERISA. In the event of Plan termination, the participants would become fully vested and entitled to receive all amounts credited to their accounts.

5. Income Tax Status

The Plan has been designed using a volume submitter plan document designed by Fidelity Management & Research Co. (Fidelity Management). Fidelity Management has received a determination letter dated June 30, 2020, in which the Internal Revenue Service (IRS) stated that the Plan, as then designed, was in compliance with the applicable requirements of the IRC. The Plan has been amended since receiving the determination letter; however, the Plan Administrator believes that the Plan is currently designed and being operated in compliance with the applicable requirements of the IRC.

**AGIOS PHARMACEUTICALS 401(K) PLAN
NOTES TO THE FINANCIAL STATEMENTS
December 31, 2025 and 2024**



Accounting principles generally accepted in the United States of America require Plan management to evaluate tax positions taken by the Plan and recognize a tax liability for any uncertain positions that more likely than not would not be sustained upon examination by the IRS. The Plan Administrator has analyzed the tax positions taken by the Plan and has concluded that as of December 31, 2025, there are no uncertain positions taken, or expected to be taken, that would require recognition of a liability or disclosure in the financial statements. The Plan is subject to routine audits by taxing jurisdictions; however, there are currently no audits in progress for any tax periods.

6. Summary of Information Certified by the Trustee

The following is a summary of financial information and data certified by Fidelity, the trustee:

Statements of Net Assets Available for Plan Benefits at December 31, 2025 and 2024, except for participant and Company contributions receivable, if any;

Investment income and interest income from participant notes receivable on the Statement of Changes in Net Assets Available for Plan Benefits for the year ended December 31, 2025; and

Investment information provided in the supplemental schedule, Schedule of Assets (Held at End of Year) at December 31, 2025.

7. Related Party and Party-in-Interest Transactions

Certain plan investments are held and managed by Fidelity, the trustee of the Plan. Therefore, these transactions qualify as party-in-interest transactions. The Plan made direct payments to Fidelity for administrative services of \$65,424 for the year ended December 31, 2025. Participant notes receivable also qualify as party-in-interest transactions.

8. Differences from Form 5500

Differences between the Annual Return/Report of Employee Benefit Plan, Form 5500, and these financial statements are a result of different classifications between line items. Total Plan assets are in agreement.

AGIOS PHARMACEUTICALS 401(K) PLAN
NOTES TO THE FINANCIAL STATEMENTS
December 31, 2025 and 2024



9. Non-exempt Transactions

During 2025, the Employer failed to remit participant contributions of \$1,297 and loan repayments of \$385 to the Plan on a timely basis as prescribed in the applicable Department of Labor Regulations 29 CFR 2510.3-102. Defined contribution plans must remit employee contributions to the Plan as soon as they can be reasonably segregated from the Employer's general assets, but no later than the 15th business day of the month following the month in which the participant contributions are withheld or received by the Employer. The Employer remitted untimely participant contributions and loan repayments totaling \$1,682 due to the Plan during the year ended December 31, 2025. The Employer is currently working with its third-party administrator to calculate and remit any lost earnings associated with these late remittances.

AGIOS PHARMACEUTICALS 401(K) PLAN
ATTACHMENT TO SCHEDULE H, PART 4, LINE 4a-
SCHEDULE OF DELINQUENT PARTICIPANT CONTRIBUTIONS
Year Ended December 31, 2025

Employer Identification Number: 26-0662915
Plan Number: 001

<u>Identity of Party Involved</u>		<u>Relationship to Plan, Employer or Other Party-in-interest</u>			
* Agios Pharmaceuticals		Employer			
<u>Total that Constitutes Non-exempt Prohibited Transactions</u>					
	<u>Participant Contributions Transferred Late to Plan</u>	<u>Contributions Not Corrected</u>	<u>Contributions Corrected Outside VFCP</u>	<u>Contributions Pending Correction in VFCP</u>	<u>Total Fully Corrected Under VFCP and PTE-2002-51</u>
(1)	\$ 1,682	\$ 1,682	\$ -	\$ -	\$ -

(1) 2025 delinquent participant contributions and loan repayments, due to failed timely remittance as prescribed in the applicable Department of Labor Regulation 29 CFR 2510.3-102, as reported on the December 31, 2025 financial statements. Principal was transmitted during the year ended December 31, 2025. Lost earnings, if any, will be remitted and corrected during 2026.

* Indicates party-in-interest to the Plan.

AGIOS PHARMACEUTICALS 401(K) PLAN
ATTACHMENT TO SCHEDULE H, PART 4, ITEM 4i -
SCHEDULE OF ASSETS (HELD AT END OF YEAR)
December 31, 2025

Employer Identification Number: 26-0662915
Plan Number: 001

(a)	(b) Identity of issue, borrower, lessor or similar party	(c) Description of investment including maturity date, rate of interest, collateral, par, or maturity value	(e) Current value
	<u>Cash and Cash Equivalents:</u>		
*	Fidelity	Government Cash Reserves	\$ 1,540
	Vanguard	Federal Money Market Fund	1,121,044
	Total Cash and Cash Equivalents		<u>1,122,584</u>
	<u>Mutual Funds:</u>		
	American Funds	Balanced R6 Fund	535,890
	American Funds	New Perspective R6 Fund	1,272,300
	American Funds	New World Fund R6	1,581,093
	Allspring	Special Small Cap Value Fund - Class R6	595,870
	DFA	Inflation Protected Securities Portfolio	722,618
	DFA	Real Estate Securities Portfolio Institutional Class	765,389
*	Fidelity	Mid Cap Index Fund	2,476,501
*	Fidelity	Small Cap Index Fund	2,228,682
	Invesco	Gold & Special Minerals Fund	657,840
	JP Morgan	Large Cap Growth Fund R6	7,673,639
	JP Morgan	Mid Cap Growth Fund R6	1,311,914
	JP Morgan	U.S. Equity Fund R6	1,145,033
	PGIM	High Yield Fund R6	436,479
	PIMCO	Income Institutional Fund	1,062,430
	Vanguard	500 Index Fund Admiral Shares	14,485,120
	Vanguard	Developed Markets Index Fund Admiral Shares	1,783,782
	Vanguard	Explorer Fund Admiral Shares	1,108,018
	Vanguard	Growth Index Fund Admiral Shares	4,217,528
	Vanguard	Materials Index Fund Admiral Shares	287,514
	Vanguard	Target Retirement 2020 Fund	165,937
	Vanguard	Target Retirement 2025 Fund	3,200,955
	Vanguard	Target Retirement 2030 Fund	6,800,042
	Vanguard	Target Retirement 2035 Fund	12,388,474
	Vanguard	Target Retirement 2040 Fund	12,506,525
	Vanguard	Target Retirement 2045 Fund	15,585,998
	Vanguard	Target Retirement 2050 Fund	13,687,839
	Vanguard	Target Retirement 2055 Fund	12,217,903
	Vanguard	Target Retirement 2060 Fund	3,780,683
	Vanguard	Target Retirement 2065 Fund	343,584
	Vanguard	Target Retirement Income Fund	214,928
	Vanguard	Value Index Fund Admiral Shares	3,191,590
	Victory	Sycamore Established Value R6 Fund	911,037
	Voya	Intermediate Bond Fund R6	708,934
	Total Mutual Funds		<u>130,052,069</u>
	<u>Common Collective Trusts:</u>		
*	Fidelity	Managed Income Portfolio Class 1	383,371
	<u>Self-directed Brokerage Accounts:</u>		
*	Fidelity	BrokerageLink Fund	1,903,274
*	Participant Loans	Interest rates ranging from 4.25% to 9.50%; maturing at various dates through October 2033, collateralized by participant's vested account balance.	715,388
			<u>\$ 134,176,686</u>

* Indicates party-in-interest to the Plan.

Note: All investments are participant directed; therefore, the unit and cost columns have been omitted.

AGIOS PHARMACEUTICALS 401(K) PLAN

**Financial Statements
and Supplemental Schedules**

December 31, 2025 and 2024

(With Independent Auditors' Report Thereon)

AGIOS PHARMACEUTICALS 401(K) PLAN

FINANCIAL STATEMENTS AND SUPPLEMENTAL SCHEDULES

December 31, 2025 and 2024

	<u>Page</u>
INDEPENDENT AUDITORS' REPORT	1
FINANCIAL STATEMENTS:	
Statements of Net Assets Available for Plan Benefits	5
Statement of Changes in Net Assets Available for Plan Benefits	6
Notes to the Financial Statements	7
SUPPLEMENTAL SCHEDULES (Note A):	
Schedule of Delinquent Participant Contributions	16
Schedule of Assets (Held at End of Year)	17

Note A: Schedules not included with this supplemental data have been omitted because they are not applicable.

INDEPENDENT AUDITORS' REPORT

To the Plan Administrator of the
Agios Pharmaceuticals 401(k) Plan:

Scope and Nature of the ERISA Section 103(a)(3)(C) Audit

We have performed audits of the financial statements of the Agios Pharmaceuticals 401(k) Plan (the Plan), an employee benefit plan subject to the Employee Retirement Income Security Act of 1974 (ERISA), as permitted by ERISA Section 103(a)(3)(C) (ERISA Section 103(a)(3)(C) audit). The financial statements comprise the Statements of Net Assets Available for Plan Benefits as of December 31, 2025 and 2024, and the related Statement of Changes in Net Assets Available for Plan Benefits for the year ended December 31, 2025, and the related notes to the financial statements.

Management, having determined it is permissible in the circumstances, has elected to have the audits of the Plan's financial statements performed in accordance with ERISA Section 103(a)(3)(C) pursuant to 29 CFR 2520.103-8 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA. As permitted by ERISA Section 103(a)(3)(C), our audits need not extend to any statements or information related to assets held for investment of the Plan (investment information) by a bank or similar institution or insurance carrier that is regulated, supervised, and subject to periodic examination by a state or federal agency, provided that the statements or information regarding assets so held are prepared and certified to by the bank or similar institution or insurance carrier in accordance with 29 CFR 2520.103-5 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA (qualified institution).

Management has obtained certifications from a qualified institution as of December 31, 2025 and 2024 and for the year ended December 31, 2025, stating that the certified investment information, as described in Note 6 to the financial statements, is complete and accurate.

Opinion

In our opinion, based on our audits and on the procedures performed as described in the Auditors' Responsibilities for the Audit of the Financial Statements section:

- the amounts and disclosures in the financial statements referred to above, other than those agreed to or derived from the certified investment information, are presented fairly, in all material respects, in accordance with accounting principles generally accepted in the United States of America.
- the information in the financial statements referred to above related to assets held by and certified to by a qualified institution agrees to, or is derived from, in all material respects, the information prepared and certified by an institution that management determined meets the requirements of ERISA Section 103(a)(3)(C).

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Plan and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our ERISA Section 103(a)(3)(C) audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error. Management's election of the ERISA Section 103(a)(3)(C) audit does not affect management's responsibility for the financial statements.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Plan's ability to continue as a going concern for one year after the date the financial statements are available to be issued.

Management is also responsible for maintaining a current plan instrument, including all plan amendments; administering the Plan; and determining that the Plan's transactions that are presented and disclosed in the financial statements are in conformity with the Plan's provisions, including maintaining sufficient records with respect to each of the participants, to determine the benefits due or which may become due to such participants.

Auditors' Responsibilities for the Audit of the Financial Statements

Except as described in the Scope and Nature of the ERISA Section 103(a)(3)(C) Audit section of our report, our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Plan's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Plan's ability to continue as a going concern for a reasonable period of time.

Our audits did not extend to the certified investment information, except for obtaining and reading the certification, comparing the certified investment information with the related information presented and disclosed in the financial statements, and reading the disclosures relating to the certified investment information to assess whether they are in accordance with the presentation and disclosure requirements of accounting principles generally accepted in the United States of America.

Accordingly, the objective of an ERISA Section 103(a)(3)(C) audit is not to express an opinion about whether the financial statements as a whole are presented fairly, in all material respects, in accordance with accounting principles generally accepted in the United States of America.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Supplemental Schedules Required by ERISA

The supplemental Schedule of Delinquent Participant Contributions for the year ended December 31, 2025 and Schedule of Assets (Held at End of Year) as of December 31, 2025 are presented for purposes of additional analysis and are not a required part of the financial statements but are supplemental information required by the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information included in the supplemental schedules, other than that agreed to or derived from the certified investment information, has been subjected to auditing procedures applied in the audits of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with GAAS. For information included in the supplemental schedules that agreed to or is derived from the certified investment information, we compared such information to the related certified investment information.

In forming our opinion on the supplemental schedules, we evaluated whether the supplemental schedules, other than the information agreed to or derived from the certified investment information, including its form and content, are presented in conformity with the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA.

In our opinion:

- the form and content of the supplemental schedules, other than the information in the supplemental schedules that agreed to or is derived from the certified investment information, are presented, in all material respects, in conformity with the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA.
- the information in the supplemental schedules related to assets held by and certified to by a qualified institution agrees to, or is derived from, in all material respects, the information prepared and certified by an institution that management determined meets the requirements of ERISA Section 103(a)(3)(C).

Kahn, Litwin, Renya & Co., Ltd.

July 16, 2026

AGIOS PHARMACEUTICALS 401(K) PLAN
STATEMENTS OF NET ASSETS AVAILABLE FOR PLAN BENEFITS
December 31, 2025 and 2024



	<u>2025</u>	<u>2024</u>
Assets		
Investments, at fair value:		
Cash and cash equivalents	\$ 1,122,584	\$ 43,592
Mutual funds	130,052,069	103,813,590
Common collective trusts	383,371	324,649
Self-directed brokerage accounts	1,903,274	1,043,734
	<u>133,461,298</u>	<u>105,225,565</u>
Receivables:		
Participant contributions	-	257,908
Company contributions	-	98,632
Participant notes	715,388	616,750
	<u>715,388</u>	<u>973,290</u>
Net Assets Available for Plan Benefits	<u>\$ 134,176,686</u>	<u>\$ 106,198,855</u>

AGIOS PHARMACEUTICALS 401(K) PLAN
STATEMENT OF CHANGES IN NET ASSETS AVAILABLE FOR PLAN BENEFITS
Year Ended December 31, 2025



Additions to net assets attributed to:

Investment income:

Interest and dividends	\$ 4,034,869
Net appreciation in fair value of investments	15,568,170
	<u>19,603,039</u>

Interest income from participant notes receivable	<u>48,550</u>
---	---------------

Contributions:

Participant	11,252,124
Company	4,107,221
Rollovers	4,830,416
	<u>20,189,761</u>

Total additions	<u>39,841,350</u>
------------------------	--------------------------

Deductions from net assets attributed to:

Benefits paid to participants	11,798,095
Administrative expenses	65,424
Total deductions	<u>11,863,519</u>

Net increase	27,977,831
---------------------	-------------------

Net Assets Available for Plan Benefits:

Beginning of year	<u>106,198,855</u>
End of year	<u>\$ 134,176,686</u>

**AGIOS PHARMACEUTICALS 401(K) PLAN
NOTES TO THE FINANCIAL STATEMENTS
December 31, 2025 and 2024**



1. Description of the Plan

The following description of the Agios Pharmaceuticals 401(k) Plan (the Plan) is intended to provide only general information regarding the Plan. Participants should refer to the Plan Document for a more complete description of the Plan's provisions.

General

The Plan is a defined contribution plan established to provide employees of Agios Pharmaceuticals (the Company or Employer) with retirement benefits in accordance with Sections 401(a) and 401(k) of the Internal Revenue Code (IRC). The Plan covers all employees of the Company upon attaining the age of 21, except those covered by a collective bargaining agreement, leased employees, non-resident aliens, temporary or contract employees, and interns. Eligible participants can enroll in the Plan at the beginning of the next payroll period following their date of hire. The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974 (ERISA).

The Company is also the administrator of the Plan. As administrator, the Company has exclusive authority and responsibility for all matters in connection with the operation and administration of the Plan. Fidelity Management Trust Company (Fidelity) is the appointed trustee of the Plan and acts at the direction of the Plan Administrator.

Contributions

Participants may make voluntary contributions through salary reductions from 1% to 75% of their eligible annual pre-tax compensation, as defined by the Plan document, limited to the maximum amounts allowed under the provisions of the IRC (\$23,500 in 2025). Further, participants who are 50 years of age or older as of December 31, 2025, may contribute an additional "catch-up" contribution (\$7,500 in 2025). The Plan also allows rollover contributions from other qualified plans, as defined in the Plan Document. Participants direct the investment of their contributions into various investment options offered by the Plan. The Plan currently offers various mutual funds, brokerage funds, and common collective trusts as investment options for participants.

Effective January 1, 2025, the Plan adopted a provision of the Setting Every Community Up for Retirement Enhancement Act of 2022 (SECURE) Act 2.0 allowing certain eligible participants to make increased catch-up elective deferrals, referred to as "super catch-up" contributions. Under this provision, the maximum catch-up deferral amount for participants between the ages of 60 and 63 increased from \$7,500 to \$11,250.

The Plan also allows participants to defer funds into a "Roth 401(k) deferral." These deferrals are subject to federal income taxes, and the maximum allowable combined contributions of the Roth 401(k) and the pre-tax deferrals is \$23,500 (\$31,000 or \$34,750 with additional "catch-up" and "super catch-up" contributions, respectively). In addition, participants can also make voluntary, non-deductible, after-tax contributions limited to 75% of eligible compensation.

**AGIOS PHARMACEUTICALS 401(K) PLAN
NOTES TO THE FINANCIAL STATEMENTS
December 31, 2025 and 2024**



The Company may make discretionary matching contributions. For the year ended December 31, 2025, the Company matched 100% of employee pre-tax and Roth 401(k) contributions up to 4% of compensation. Participant voluntary, non-deductible, after-tax contributions are not eligible for matching contributions. For the plan year ended December 31, 2025, the Company made matching contributions of \$4,107,221.

Participant Accounts

Each participant's account is credited with the participant's contributions, the Company's matching contributions and their allocation of Plan earnings/losses and any expenses incurred. Allocations are based on participant compensation or individual account balances, as defined. The benefit to which a participant is entitled is the benefit that can be provided from the participant's vested account.

Vesting

Participants are immediately vested in their voluntary contributions, rollover contributions, discretionary matching contributions, and earnings thereon.

Participant Notes Receivable

Participants may borrow from their account a minimum of \$1,000 up to a maximum equal to the lesser of \$50,000 within a 12-month period or 50% of their vested account balance. A participant can only have one loan outstanding at any time. Terms range from 1 to 5 years, or up to 10 years for the purchase of a primary residence. The notes are secured by the vested balance in the participant's account and bear interest at a rate determined reasonable by the Plan Administrator as defined in the Plan document. The interest rate is fixed for the term of the loan. Principal and interest is paid ratably through payroll deductions.

The Plan allows terminated participants with an outstanding loan to continue making payments after termination in accordance with the promissory note.

Forfeitures

As of December 31, 2025 and 2024, forfeited non-vested accounts totaled \$11,863 and \$9,575, respectively. These accounts may be used to pay administrative expenses or reduce future Company contributions. For the year ended December 31, 2025, \$50 of the forfeiture balance was used to pay administrative expenses.

Payment of Benefits

The Plan allows for in-service distributions of the participant's vested accounts upon reaching the age of 59 ½ or due to hardship, as defined by the Plan. In-service withdrawals are also permitted for Rollover and Roth Rollover account balances at any time. The Plan also provides for mandatory distributions to participants upon reaching the age of 73. Upon retirement, death, disability or termination of employment, a participant (or participant's beneficiary in the event of death) will be entitled to 100% of their vested account balance, payable in a single lump-sum distribution.

**AGIOS PHARMACEUTICALS 401(K) PLAN
NOTES TO THE FINANCIAL STATEMENTS
December 31, 2025 and 2024**



If a participant's vested balance is equal to or less than \$1,000, the participant will receive an immediate cash-out of their vested account balance, and the non-vested portion shall be treated as a forfeiture. If a participant's vested balance exceeds \$1,000 and is equal to or less than \$7,000, the amount will be rolled over to an individual retirement plan designated by the trustee, unless otherwise directed by the participant.

Hardship Withdrawals

Hardship withdrawals are allowed under the provisions of the Plan and cannot exceed the amount required to meet the immediate financial need created by the hardship.

2. Summary of Significant Accounting Policies

Basis of Accounting

The Plan's financial statements have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America.

Valuation of Investments and Income Recognition

The Plan's investments are reported at fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (Note 3). The Plan invests in the Fidelity Managed Income Portfolio (MIP), which is a common collective trust fund. The Plan's interest in the MIP is valued at the net asset value (NAV) practical expedient of the underlying investments reported by the issuer of the common collective trust at year-end. The Plan Administrator determines the Plan's valuation policies utilizing information provided by the investment advisors and trustee.

Purchases and sales of securities are recorded on a trade-date basis. Dividends are recorded on the ex-dividend date. Interest income is recorded on the accrual basis. Net appreciation or depreciation includes the Plan's gains and losses on investments bought and sold, as well as held during the year.

Participant Notes Receivable

Participant notes receivable are measured at their unpaid principal balances plus any accrued but unpaid interest and are secured by the balance in the respective participant's account.

Related fees are recorded as administrative expenses and are expensed when they are incurred. Interest income on participant notes receivable is recorded when it is earned. A receivable is considered past due if payment has not been received within the stated terms. Delinquent participant notes receivable are reclassified as distributions based on terms of the Plan Document.

Contributions

Participant and Company matching contributions are recorded bi-weekly or semi-monthly when the Company remits the contributions for investment into the Plan.

**AGIOS PHARMACEUTICALS 401(K) PLAN
NOTES TO THE FINANCIAL STATEMENTS
December 31, 2025 and 2024**



Payment of Benefits

Benefits are recorded when paid to participants or their designated beneficiaries.

Administrative Expenses

Certain administrative expenses of the Plan are paid by the Company, unless the Company directs that such expenses be paid by the Plan. Expenses that are paid by the Company are excluded from these financial statements. Investment management and recordkeeping fees, if applicable, are paid by the Plan through revenue sharing as a reduction of investment income (net appreciation or depreciation) from the related investment fund. Participant notes receivable set-up and administration fees are charged directly against a participant's account on a pro-rata basis from all of the funds in which the respective participant is invested at the time the fees are taken and are included in administrative expenses.

Estimates

The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires the Plan Administrator to make estimates and assumptions that affect certain reported amounts of assets, liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported changes in net assets. Accordingly, actual results may differ from those estimates.

Risks and Uncertainties

The Plan provides for various investment options with a variety of investment objectives. Investment securities are exposed to various risks such as interest rate risk, market risk and credit risk. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect participants' account balances and the amounts reported in the Statements of Net Assets Available for Plan Benefits.

The Plan invested in three and four mutual funds that accounted for approximately 33% and 44% of total Plan investments as of December 31, 2025 and 2024, respectively.

Financial Instruments with a Concentration of Credit Risk

The Plan's investments are held by a single trustee. The Plan's exposure to credit risk is associated with the outside entity's non-performance of their fiduciary responsibilities relating to these amounts as specified in the agreements. Benefits provided by the Plan are not insured or guaranteed by the Pension Benefit Guaranty Corporation.

Subsequent Events

Management has evaluated subsequent events through July 16, 2026, which is the date these financial statements were available to be issued.

AGIOS PHARMACEUTICALS 401(K) PLAN
NOTES TO THE FINANCIAL STATEMENTS
December 31, 2025 and 2024



3. Fair Value Measurements

The framework for measuring fair value provides a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives highest priority to unadjusted quoted prices in active markets for identical assets (level 1) and the lowest priority to unobservable inputs (level 3).

The three levels of the fair value hierarchy and inputs to the valuation methodologies are described as follows:

Level 1 inputs are unadjusted quoted prices in active markets for identical assets the Plan has the ability to access.

Level 2 inputs are other than quoted prices in active markets that are observable either directly or indirectly for the asset. Such inputs are derived principally from or corroborated by observable market data for similar assets by correlation or other means, over substantially the full contractual term of the asset, if applicable.

Level 3 inputs are unobservable and significant to the fair value measurement. Such inputs generally rely on the Plan's own assumptions about the assumptions that market participants would use in pricing the asset.

The asset's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques maximize the use of relevant observable inputs and minimize the use of unobservable inputs.

The following is a description of the valuation methodologies used for assets measured at fair value on a recurring basis.

Cash and Cash Equivalents: The carrying amounts of cash and cash equivalents are valued at deposit amount plus accrued interest, as determined according to stated terms.

Mutual Funds: Valued at the daily closing price as reported by the fund. Mutual funds held by the Plan are open-end mutual funds that are registered with the Securities and Exchange Commission. These funds are required to publish their daily NAV and to transact at that price. The mutual funds held by the Plan are deemed to be actively traded.

Self-directed Brokerage Accounts: Valued at the closing price reported on the active market on which the individual securities are traded. This account consists of cash, common stock, mutual funds and federal bonds.

AGIOS PHARMACEUTICALS 401(K) PLAN
NOTES TO THE FINANCIAL STATEMENTS
December 31, 2025 and 2024



Common Collective Trust: The Plan invests in the Fidelity Managed Income Portfolio, an investment vehicle that invests in benefit-responsive investment contracts, fixed income securities and money market funds. Units held are valued at NAV. The NAV, as provided by Fidelity, is used as a practical expedient to estimate fair value. The NAV is based on the fair value of the underlying investments held by the fund less its liabilities.

This practical expedient is not used when it is determined to be probable that the fund will sell the investment for an amount different than the reported NAV. Unit values are determined by dividing the fund's net assets at fair value by its units outstanding at the valuation dates. Participant transactions (purchases and sales) may occur daily. There are no unfunded commitments or redemption restrictions for the Plan, however, there is up to a 12-month redemption for this investment at the Plan level.

As of December 31, 2025, the Plan's investments are reported at fair value in the accompanying Statements of Net Assets Available for Plan Benefits as follows:

	Level 1	Total
Cash and cash equivalents	\$ 1,122,584	\$ 1,122,584
Mutual funds	130,052,069	130,052,069
Self-directed brokerage accounts	1,903,274	1,903,274
Total assets in the fair value hierarchy	<u>133,077,927</u>	<u>133,077,927</u>
Common collective trust measured at NAV (a)		<u>383,371</u>
Total investments at fair value		<u><u>\$ 133,461,298</u></u>

AGIOS PHARMACEUTICALS 401(K) PLAN
NOTES TO THE FINANCIAL STATEMENTS
December 31, 2025 and 2024



As of December 31, 2024, the Plan's investments are reported at fair value in the accompanying Statements of Net Assets Available for Plan Benefits as follows:

	Level 1	Total
Cash and cash equivalents	\$ 43,592	\$ 43,592
Mutual funds	103,813,590	103,813,590
Self-directed brokerage accounts	1,043,734	1,043,734
Total assets in the fair value hierarchy	<u>104,900,916</u>	<u>104,900,916</u>
Common collective trust measured at NAV (a)		<u>324,649</u>
Total investments at fair value		<u><u>\$ 105,225,565</u></u>

(a) In accordance with Subtopic 820-10, the common collective trust funds were measured at NAV per share (or its equivalent) and have not been classified in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value to the line items presented in the Statements of Net Assets Available for Plan Benefits.

4. Plan Termination

The Company expects to continue the Plan indefinitely. However, the Company reserves the right to amend the Plan or contributions thereto, at any time and in any manner that it deems advisable, provided that no amendment shall have the effect of diverting Plan assets for purposes other than for the exclusive benefit of the Plan participants and any Plan termination would be subject to the provisions of ERISA. In the event of Plan termination, the participants would become fully vested and entitled to receive all amounts credited to their accounts.

5. Income Tax Status

The Plan has been designed using a volume submitter plan document designed by Fidelity Management & Research Co. (Fidelity Management). Fidelity Management has received a determination letter dated June 30, 2020, in which the Internal Revenue Service (IRS) stated that the Plan, as then designed, was in compliance with the applicable requirements of the IRC. The Plan has been amended since receiving the determination letter; however, the Plan Administrator believes that the Plan is currently designed and being operated in compliance with the applicable requirements of the IRC.

**AGIOS PHARMACEUTICALS 401(K) PLAN
NOTES TO THE FINANCIAL STATEMENTS
December 31, 2025 and 2024**



Accounting principles generally accepted in the United States of America require Plan management to evaluate tax positions taken by the Plan and recognize a tax liability for any uncertain positions that more likely than not would not be sustained upon examination by the IRS. The Plan Administrator has analyzed the tax positions taken by the Plan and has concluded that as of December 31, 2025, there are no uncertain positions taken, or expected to be taken, that would require recognition of a liability or disclosure in the financial statements. The Plan is subject to routine audits by taxing jurisdictions; however, there are currently no audits in progress for any tax periods.

6. Summary of Information Certified by the Trustee

The following is a summary of financial information and data certified by Fidelity, the trustee:

Statements of Net Assets Available for Plan Benefits at December 31, 2025 and 2024, except for participant and Company contributions receivable, if any;

Investment income and interest income from participant notes receivable on the Statement of Changes in Net Assets Available for Plan Benefits for the year ended December 31, 2025; and

Investment information provided in the supplemental schedule, Schedule of Assets (Held at End of Year) at December 31, 2025.

7. Related Party and Party-in-Interest Transactions

Certain plan investments are held and managed by Fidelity, the trustee of the Plan. Therefore, these transactions qualify as party-in-interest transactions. The Plan made direct payments to Fidelity for administrative services of \$65,424 for the year ended December 31, 2025. Participant notes receivable also qualify as party-in-interest transactions.

8. Differences from Form 5500

Differences between the Annual Return/Report of Employee Benefit Plan, Form 5500, and these financial statements are a result of different classifications between line items. Total Plan assets are in agreement.

AGIOS PHARMACEUTICALS 401(K) PLAN
NOTES TO THE FINANCIAL STATEMENTS
December 31, 2025 and 2024



9. Non-exempt Transactions

During 2025, the Employer failed to remit participant contributions of \$1,297 and loan repayments of \$385 to the Plan on a timely basis as prescribed in the applicable Department of Labor Regulations 29 CFR 2510.3-102. Defined contribution plans must remit employee contributions to the Plan as soon as they can be reasonably segregated from the Employer's general assets, but no later than the 15th business day of the month following the month in which the participant contributions are withheld or received by the Employer. The Employer remitted untimely participant contributions and loan repayments totaling \$1,682 due to the Plan during the year ended December 31, 2025. The Employer is currently working with its third-party administrator to calculate and remit any lost earnings associated with these late remittances.

AGIOS PHARMACEUTICALS 401(K) PLAN
ATTACHMENT TO SCHEDULE H, PART 4, LINE 4a-
SCHEDULE OF DELINQUENT PARTICIPANT CONTRIBUTIONS
Year Ended December 31, 2025

Employer Identification Number: 26-0662915
Plan Number: 001

<u>Identity of Party Involved</u>		<u>Relationship to Plan, Employer or Other Party-in-interest</u>			
* Agios Pharmaceuticals		Employer			
<u>Total that Constitutes Non-exempt Prohibited Transactions</u>					
	<u>Participant Contributions Transferred Late to Plan</u>	<u>Contributions Not Corrected</u>	<u>Contributions Corrected Outside VFCP</u>	<u>Contributions Pending Correction in VFCP</u>	<u>Total Fully Corrected Under VFCP and PTE-2002-51</u>
(1)	\$ 1,682	\$ 1,682	\$ -	\$ -	\$ -

(1) 2025 delinquent participant contributions and loan repayments, due to failed timely remittance as prescribed in the applicable Department of Labor Regulation 29 CFR 2510.3-102, as reported on the December 31, 2025 financial statements. Principal was transmitted during the year ended December 31, 2025. Lost earnings, if any, will be remitted and corrected during 2026.

* Indicates party-in-interest to the Plan.

AGIOS PHARMACEUTICALS 401(K) PLAN
ATTACHMENT TO SCHEDULE H, PART 4, ITEM 4i -
SCHEDULE OF ASSETS (HELD AT END OF YEAR)
December 31, 2025

Employer Identification Number: 26-0662915
Plan Number: 001

(a)	(b) Identity of issue, borrower, lessor or similar party	(c) Description of investment including maturity date, rate of interest, collateral, par, or maturity value	(e) Current value
	<u>Cash and Cash Equivalents:</u>		
*	Fidelity	Government Cash Reserves	\$ 1,540
	Vanguard	Federal Money Market Fund	1,121,044
	Total Cash and Cash Equivalents		<u>1,122,584</u>
	<u>Mutual Funds:</u>		
	American Funds	Balanced R6 Fund	535,890
	American Funds	New Perspective R6 Fund	1,272,300
	American Funds	New World Fund R6	1,581,093
	Allspring	Special Small Cap Value Fund - Class R6	595,870
	DFA	Inflation Protected Securities Portfolio	722,618
	DFA	Real Estate Securities Portfolio Institutional Class	765,389
*	Fidelity	Mid Cap Index Fund	2,476,501
*	Fidelity	Small Cap Index Fund	2,228,682
	Invesco	Gold & Special Minerals Fund	657,840
	JP Morgan	Large Cap Growth Fund R6	7,673,639
	JP Morgan	Mid Cap Growth Fund R6	1,311,914
	JP Morgan	U.S. Equity Fund R6	1,145,033
	PGIM	High Yield Fund R6	436,479
	PIMCO	Income Institutional Fund	1,062,430
	Vanguard	500 Index Fund Admiral Shares	14,485,120
	Vanguard	Developed Markets Index Fund Admiral Shares	1,783,782
	Vanguard	Explorer Fund Admiral Shares	1,108,018
	Vanguard	Growth Index Fund Admiral Shares	4,217,528
	Vanguard	Materials Index Fund Admiral Shares	287,514
	Vanguard	Target Retirement 2020 Fund	165,937
	Vanguard	Target Retirement 2025 Fund	3,200,955
	Vanguard	Target Retirement 2030 Fund	6,800,042
	Vanguard	Target Retirement 2035 Fund	12,388,474
	Vanguard	Target Retirement 2040 Fund	12,506,525
	Vanguard	Target Retirement 2045 Fund	15,585,998
	Vanguard	Target Retirement 2050 Fund	13,687,839
	Vanguard	Target Retirement 2055 Fund	12,217,903
	Vanguard	Target Retirement 2060 Fund	3,780,683
	Vanguard	Target Retirement 2065 Fund	343,584
	Vanguard	Target Retirement Income Fund	214,928
	Vanguard	Value Index Fund Admiral Shares	3,191,590
	Victory	Sycamore Established Value R6 Fund	911,037
	Voya	Intermediate Bond Fund R6	708,934
	Total Mutual Funds		<u>130,052,069</u>
	<u>Common Collective Trusts:</u>		
*	Fidelity	Managed Income Portfolio Class 1	383,371
	<u>Self-directed Brokerage Accounts:</u>		
*	Fidelity	BrokerageLink Fund	1,903,274
*	Participant Loans	Interest rates ranging from 4.25% to 9.50%; maturing at various dates through October 2033, collateralized by participant's vested account balance.	715,388
			<u>\$ 134,176,686</u>

* Indicates party-in-interest to the Plan.

Note: All investments are participant directed; therefore, the unit and cost columns have been omitted.

AGIOS PHARMACEUTICALS 401(K) PLAN

**Financial Statements
and Supplemental Schedules**

December 31, 2025 and 2024

(With Independent Auditors' Report Thereon)

AGIOS PHARMACEUTICALS 401(K) PLAN

FINANCIAL STATEMENTS AND SUPPLEMENTAL SCHEDULES

December 31, 2025 and 2024

	<u>Page</u>
INDEPENDENT AUDITORS' REPORT	1
FINANCIAL STATEMENTS:	
Statements of Net Assets Available for Plan Benefits	5
Statement of Changes in Net Assets Available for Plan Benefits	6
Notes to the Financial Statements	7
SUPPLEMENTAL SCHEDULES (Note A):	
Schedule of Delinquent Participant Contributions	16
Schedule of Assets (Held at End of Year)	17

Note A: Schedules not included with this supplemental data have been omitted because they are not applicable.

INDEPENDENT AUDITORS' REPORT

To the Plan Administrator of the
Agios Pharmaceuticals 401(k) Plan:

Scope and Nature of the ERISA Section 103(a)(3)(C) Audit

We have performed audits of the financial statements of the Agios Pharmaceuticals 401(k) Plan (the Plan), an employee benefit plan subject to the Employee Retirement Income Security Act of 1974 (ERISA), as permitted by ERISA Section 103(a)(3)(C) (ERISA Section 103(a)(3)(C) audit). The financial statements comprise the Statements of Net Assets Available for Plan Benefits as of December 31, 2025 and 2024, and the related Statement of Changes in Net Assets Available for Plan Benefits for the year ended December 31, 2025, and the related notes to the financial statements.

Management, having determined it is permissible in the circumstances, has elected to have the audits of the Plan's financial statements performed in accordance with ERISA Section 103(a)(3)(C) pursuant to 29 CFR 2520.103-8 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA. As permitted by ERISA Section 103(a)(3)(C), our audits need not extend to any statements or information related to assets held for investment of the Plan (investment information) by a bank or similar institution or insurance carrier that is regulated, supervised, and subject to periodic examination by a state or federal agency, provided that the statements or information regarding assets so held are prepared and certified to by the bank or similar institution or insurance carrier in accordance with 29 CFR 2520.103-5 of the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA (qualified institution).

Management has obtained certifications from a qualified institution as of December 31, 2025 and 2024 and for the year ended December 31, 2025, stating that the certified investment information, as described in Note 6 to the financial statements, is complete and accurate.

Opinion

In our opinion, based on our audits and on the procedures performed as described in the Auditors' Responsibilities for the Audit of the Financial Statements section:

- the amounts and disclosures in the financial statements referred to above, other than those agreed to or derived from the certified investment information, are presented fairly, in all material respects, in accordance with accounting principles generally accepted in the United States of America.
- the information in the financial statements referred to above related to assets held by and certified to by a qualified institution agrees to, or is derived from, in all material respects, the information prepared and certified by an institution that management determined meets the requirements of ERISA Section 103(a)(3)(C).

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Plan and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our ERISA Section 103(a)(3)(C) audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error. Management's election of the ERISA Section 103(a)(3)(C) audit does not affect management's responsibility for the financial statements.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Plan's ability to continue as a going concern for one year after the date the financial statements are available to be issued.

Management is also responsible for maintaining a current plan instrument, including all plan amendments; administering the Plan; and determining that the Plan's transactions that are presented and disclosed in the financial statements are in conformity with the Plan's provisions, including maintaining sufficient records with respect to each of the participants, to determine the benefits due or which may become due to such participants.

Auditors' Responsibilities for the Audit of the Financial Statements

Except as described in the Scope and Nature of the ERISA Section 103(a)(3)(C) Audit section of our report, our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Plan's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Plan's ability to continue as a going concern for a reasonable period of time.

Our audits did not extend to the certified investment information, except for obtaining and reading the certification, comparing the certified investment information with the related information presented and disclosed in the financial statements, and reading the disclosures relating to the certified investment information to assess whether they are in accordance with the presentation and disclosure requirements of accounting principles generally accepted in the United States of America.

Accordingly, the objective of an ERISA Section 103(a)(3)(C) audit is not to express an opinion about whether the financial statements as a whole are presented fairly, in all material respects, in accordance with accounting principles generally accepted in the United States of America.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Supplemental Schedules Required by ERISA

The supplemental Schedule of Delinquent Participant Contributions for the year ended December 31, 2025 and Schedule of Assets (Held at End of Year) as of December 31, 2025 are presented for purposes of additional analysis and are not a required part of the financial statements but are supplemental information required by the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information included in the supplemental schedules, other than that agreed to or derived from the certified investment information, has been subjected to auditing procedures applied in the audits of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with GAAS. For information included in the supplemental schedules that agreed to or is derived from the certified investment information, we compared such information to the related certified investment information.

In forming our opinion on the supplemental schedules, we evaluated whether the supplemental schedules, other than the information agreed to or derived from the certified investment information, including its form and content, are presented in conformity with the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA.

In our opinion:

- the form and content of the supplemental schedules, other than the information in the supplemental schedules that agreed to or is derived from the certified investment information, are presented, in all material respects, in conformity with the Department of Labor's Rules and Regulations for Reporting and Disclosure under ERISA.
- the information in the supplemental schedules related to assets held by and certified to by a qualified institution agrees to, or is derived from, in all material respects, the information prepared and certified by an institution that management determined meets the requirements of ERISA Section 103(a)(3)(C).

Kahn, Litwin, Renya & Co., Ltd.

July 16, 2026

AGIOS PHARMACEUTICALS 401(K) PLAN
STATEMENTS OF NET ASSETS AVAILABLE FOR PLAN BENEFITS
December 31, 2025 and 2024



	<u>2025</u>	<u>2024</u>
Assets		
Investments, at fair value:		
Cash and cash equivalents	\$ 1,122,584	\$ 43,592
Mutual funds	130,052,069	103,813,590
Common collective trusts	383,371	324,649
Self-directed brokerage accounts	1,903,274	1,043,734
	<u>133,461,298</u>	<u>105,225,565</u>
Receivables:		
Participant contributions	-	257,908
Company contributions	-	98,632
Participant notes	715,388	616,750
	<u>715,388</u>	<u>973,290</u>
Net Assets Available for Plan Benefits	<u>\$ 134,176,686</u>	<u>\$ 106,198,855</u>

AGIOS PHARMACEUTICALS 401(K) PLAN
STATEMENT OF CHANGES IN NET ASSETS AVAILABLE FOR PLAN BENEFITS
Year Ended December 31, 2025



Additions to net assets attributed to:

Investment income:

Interest and dividends	\$ 4,034,869
Net appreciation in fair value of investments	15,568,170
	<u>19,603,039</u>

Interest income from participant notes receivable	<u>48,550</u>
---	---------------

Contributions:

Participant	11,252,124
Company	4,107,221
Rollovers	4,830,416
	<u>20,189,761</u>

Total additions	<u>39,841,350</u>
------------------------	--------------------------

Deductions from net assets attributed to:

Benefits paid to participants	11,798,095
Administrative expenses	65,424
Total deductions	<u>11,863,519</u>

Net increase	27,977,831
---------------------	-------------------

Net Assets Available for Plan Benefits:

Beginning of year	<u>106,198,855</u>
End of year	<u><u>\$ 134,176,686</u></u>

**AGIOS PHARMACEUTICALS 401(K) PLAN
NOTES TO THE FINANCIAL STATEMENTS
December 31, 2025 and 2024**



1. Description of the Plan

The following description of the Agios Pharmaceuticals 401(k) Plan (the Plan) is intended to provide only general information regarding the Plan. Participants should refer to the Plan Document for a more complete description of the Plan's provisions.

General

The Plan is a defined contribution plan established to provide employees of Agios Pharmaceuticals (the Company or Employer) with retirement benefits in accordance with Sections 401(a) and 401(k) of the Internal Revenue Code (IRC). The Plan covers all employees of the Company upon attaining the age of 21, except those covered by a collective bargaining agreement, leased employees, non-resident aliens, temporary or contract employees, and interns. Eligible participants can enroll in the Plan at the beginning of the next payroll period following their date of hire. The Plan is subject to the provisions of the Employee Retirement Income Security Act of 1974 (ERISA).

The Company is also the administrator of the Plan. As administrator, the Company has exclusive authority and responsibility for all matters in connection with the operation and administration of the Plan. Fidelity Management Trust Company (Fidelity) is the appointed trustee of the Plan and acts at the direction of the Plan Administrator.

Contributions

Participants may make voluntary contributions through salary reductions from 1% to 75% of their eligible annual pre-tax compensation, as defined by the Plan document, limited to the maximum amounts allowed under the provisions of the IRC (\$23,500 in 2025). Further, participants who are 50 years of age or older as of December 31, 2025, may contribute an additional "catch-up" contribution (\$7,500 in 2025). The Plan also allows rollover contributions from other qualified plans, as defined in the Plan Document. Participants direct the investment of their contributions into various investment options offered by the Plan. The Plan currently offers various mutual funds, brokerage funds, and common collective trusts as investment options for participants.

Effective January 1, 2025, the Plan adopted a provision of the Setting Every Community Up for Retirement Enhancement Act of 2022 (SECURE) Act 2.0 allowing certain eligible participants to make increased catch-up elective deferrals, referred to as "super catch-up" contributions. Under this provision, the maximum catch-up deferral amount for participants between the ages of 60 and 63 increased from \$7,500 to \$11,250.

The Plan also allows participants to defer funds into a "Roth 401(k) deferral." These deferrals are subject to federal income taxes, and the maximum allowable combined contributions of the Roth 401(k) and the pre-tax deferrals is \$23,500 (\$31,000 or \$34,750 with additional "catch-up" and "super catch-up" contributions, respectively). In addition, participants can also make voluntary, non-deductible, after-tax contributions limited to 75% of eligible compensation.

**AGIOS PHARMACEUTICALS 401(K) PLAN
NOTES TO THE FINANCIAL STATEMENTS
December 31, 2025 and 2024**



The Company may make discretionary matching contributions. For the year ended December 31, 2025, the Company matched 100% of employee pre-tax and Roth 401(k) contributions up to 4% of compensation. Participant voluntary, non-deductible, after-tax contributions are not eligible for matching contributions. For the plan year ended December 31, 2025, the Company made matching contributions of \$4,107,221.

Participant Accounts

Each participant's account is credited with the participant's contributions, the Company's matching contributions and their allocation of Plan earnings/losses and any expenses incurred. Allocations are based on participant compensation or individual account balances, as defined. The benefit to which a participant is entitled is the benefit that can be provided from the participant's vested account.

Vesting

Participants are immediately vested in their voluntary contributions, rollover contributions, discretionary matching contributions, and earnings thereon.

Participant Notes Receivable

Participants may borrow from their account a minimum of \$1,000 up to a maximum equal to the lesser of \$50,000 within a 12-month period or 50% of their vested account balance. A participant can only have one loan outstanding at any time. Terms range from 1 to 5 years, or up to 10 years for the purchase of a primary residence. The notes are secured by the vested balance in the participant's account and bear interest at a rate determined reasonable by the Plan Administrator as defined in the Plan document. The interest rate is fixed for the term of the loan. Principal and interest is paid ratably through payroll deductions.

The Plan allows terminated participants with an outstanding loan to continue making payments after termination in accordance with the promissory note.

Forfeitures

As of December 31, 2025 and 2024, forfeited non-vested accounts totaled \$11,863 and \$9,575, respectively. These accounts may be used to pay administrative expenses or reduce future Company contributions. For the year ended December 31, 2025, \$50 of the forfeiture balance was used to pay administrative expenses.

Payment of Benefits

The Plan allows for in-service distributions of the participant's vested accounts upon reaching the age of 59 ½ or due to hardship, as defined by the Plan. In-service withdrawals are also permitted for Rollover and Roth Rollover account balances at any time. The Plan also provides for mandatory distributions to participants upon reaching the age of 73. Upon retirement, death, disability or termination of employment, a participant (or participant's beneficiary in the event of death) will be entitled to 100% of their vested account balance, payable in a single lump-sum distribution.

**AGIOS PHARMACEUTICALS 401(K) PLAN
NOTES TO THE FINANCIAL STATEMENTS
December 31, 2025 and 2024**



If a participant's vested balance is equal to or less than \$1,000, the participant will receive an immediate cash-out of their vested account balance, and the non-vested portion shall be treated as a forfeiture. If a participant's vested balance exceeds \$1,000 and is equal to or less than \$7,000, the amount will be rolled over to an individual retirement plan designated by the trustee, unless otherwise directed by the participant.

Hardship Withdrawals

Hardship withdrawals are allowed under the provisions of the Plan and cannot exceed the amount required to meet the immediate financial need created by the hardship.

2. Summary of Significant Accounting Policies

Basis of Accounting

The Plan's financial statements have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America.

Valuation of Investments and Income Recognition

The Plan's investments are reported at fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (Note 3). The Plan invests in the Fidelity Managed Income Portfolio (MIP), which is a common collective trust fund. The Plan's interest in the MIP is valued at the net asset value (NAV) practical expedient of the underlying investments reported by the issuer of the common collective trust at year-end. The Plan Administrator determines the Plan's valuation policies utilizing information provided by the investment advisors and trustee.

Purchases and sales of securities are recorded on a trade-date basis. Dividends are recorded on the ex-dividend date. Interest income is recorded on the accrual basis. Net appreciation or depreciation includes the Plan's gains and losses on investments bought and sold, as well as held during the year.

Participant Notes Receivable

Participant notes receivable are measured at their unpaid principal balances plus any accrued but unpaid interest and are secured by the balance in the respective participant's account.

Related fees are recorded as administrative expenses and are expensed when they are incurred. Interest income on participant notes receivable is recorded when it is earned. A receivable is considered past due if payment has not been received within the stated terms. Delinquent participant notes receivable are reclassified as distributions based on terms of the Plan Document.

Contributions

Participant and Company matching contributions are recorded bi-weekly or semi-monthly when the Company remits the contributions for investment into the Plan.

**AGIOS PHARMACEUTICALS 401(K) PLAN
NOTES TO THE FINANCIAL STATEMENTS
December 31, 2025 and 2024**



Payment of Benefits

Benefits are recorded when paid to participants or their designated beneficiaries.

Administrative Expenses

Certain administrative expenses of the Plan are paid by the Company, unless the Company directs that such expenses be paid by the Plan. Expenses that are paid by the Company are excluded from these financial statements. Investment management and recordkeeping fees, if applicable, are paid by the Plan through revenue sharing as a reduction of investment income (net appreciation or depreciation) from the related investment fund. Participant notes receivable set-up and administration fees are charged directly against a participant's account on a pro-rata basis from all of the funds in which the respective participant is invested at the time the fees are taken and are included in administrative expenses.

Estimates

The preparation of financial statements in accordance with accounting principles generally accepted in the United States of America requires the Plan Administrator to make estimates and assumptions that affect certain reported amounts of assets, liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported changes in net assets. Accordingly, actual results may differ from those estimates.

Risks and Uncertainties

The Plan provides for various investment options with a variety of investment objectives. Investment securities are exposed to various risks such as interest rate risk, market risk and credit risk. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of investment securities will occur in the near term and that such changes could materially affect participants' account balances and the amounts reported in the Statements of Net Assets Available for Plan Benefits.

The Plan invested in three and four mutual funds that accounted for approximately 33% and 44% of total Plan investments as of December 31, 2025 and 2024, respectively.

Financial Instruments with a Concentration of Credit Risk

The Plan's investments are held by a single trustee. The Plan's exposure to credit risk is associated with the outside entity's non-performance of their fiduciary responsibilities relating to these amounts as specified in the agreements. Benefits provided by the Plan are not insured or guaranteed by the Pension Benefit Guaranty Corporation.

Subsequent Events

Management has evaluated subsequent events through July 16, 2026, which is the date these financial statements were available to be issued.

AGIOS PHARMACEUTICALS 401(K) PLAN
NOTES TO THE FINANCIAL STATEMENTS
December 31, 2025 and 2024



3. Fair Value Measurements

The framework for measuring fair value provides a hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives highest priority to unadjusted quoted prices in active markets for identical assets (level 1) and the lowest priority to unobservable inputs (level 3).

The three levels of the fair value hierarchy and inputs to the valuation methodologies are described as follows:

Level 1 inputs are unadjusted quoted prices in active markets for identical assets the Plan has the ability to access.

Level 2 inputs are other than quoted prices in active markets that are observable either directly or indirectly for the asset. Such inputs are derived principally from or corroborated by observable market data for similar assets by correlation or other means, over substantially the full contractual term of the asset, if applicable.

Level 3 inputs are unobservable and significant to the fair value measurement. Such inputs generally rely on the Plan's own assumptions about the assumptions that market participants would use in pricing the asset.

The asset's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques maximize the use of relevant observable inputs and minimize the use of unobservable inputs.

The following is a description of the valuation methodologies used for assets measured at fair value on a recurring basis.

Cash and Cash Equivalents: The carrying amounts of cash and cash equivalents are valued at deposit amount plus accrued interest, as determined according to stated terms.

Mutual Funds: Valued at the daily closing price as reported by the fund. Mutual funds held by the Plan are open-end mutual funds that are registered with the Securities and Exchange Commission. These funds are required to publish their daily NAV and to transact at that price. The mutual funds held by the Plan are deemed to be actively traded.

Self-directed Brokerage Accounts: Valued at the closing price reported on the active market on which the individual securities are traded. This account consists of cash, common stock, mutual funds and federal bonds.

AGIOS PHARMACEUTICALS 401(K) PLAN
NOTES TO THE FINANCIAL STATEMENTS
December 31, 2025 and 2024



Common Collective Trust: The Plan invests in the Fidelity Managed Income Portfolio, an investment vehicle that invests in benefit-responsive investment contracts, fixed income securities and money market funds. Units held are valued at NAV. The NAV, as provided by Fidelity, is used as a practical expedient to estimate fair value. The NAV is based on the fair value of the underlying investments held by the fund less its liabilities.

This practical expedient is not used when it is determined to be probable that the fund will sell the investment for an amount different than the reported NAV. Unit values are determined by dividing the fund's net assets at fair value by its units outstanding at the valuation dates. Participant transactions (purchases and sales) may occur daily. There are no unfunded commitments or redemption restrictions for the Plan, however, there is up to a 12-month redemption for this investment at the Plan level.

As of December 31, 2025, the Plan's investments are reported at fair value in the accompanying Statements of Net Assets Available for Plan Benefits as follows:

	Level 1	Total
Cash and cash equivalents	\$ 1,122,584	\$ 1,122,584
Mutual funds	130,052,069	130,052,069
Self-directed brokerage accounts	1,903,274	1,903,274
Total assets in the fair value hierarchy	<u>133,077,927</u>	<u>133,077,927</u>
Common collective trust measured at NAV (a)		<u>383,371</u>
Total investments at fair value		<u><u>\$ 133,461,298</u></u>

AGIOS PHARMACEUTICALS 401(K) PLAN
NOTES TO THE FINANCIAL STATEMENTS
December 31, 2025 and 2024



As of December 31, 2024, the Plan's investments are reported at fair value in the accompanying Statements of Net Assets Available for Plan Benefits as follows:

	Level 1	Total
Cash and cash equivalents	\$ 43,592	\$ 43,592
Mutual funds	103,813,590	103,813,590
Self-directed brokerage accounts	1,043,734	1,043,734
Total assets in the fair value hierarchy	<u>104,900,916</u>	<u>104,900,916</u>
Common collective trust measured at NAV (a)		<u>324,649</u>
Total investments at fair value		<u>\$ 105,225,565</u>

(a) In accordance with Subtopic 820-10, the common collective trust funds were measured at NAV per share (or its equivalent) and have not been classified in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value to the line items presented in the Statements of Net Assets Available for Plan Benefits.

4. Plan Termination

The Company expects to continue the Plan indefinitely. However, the Company reserves the right to amend the Plan or contributions thereto, at any time and in any manner that it deems advisable, provided that no amendment shall have the effect of diverting Plan assets for purposes other than for the exclusive benefit of the Plan participants and any Plan termination would be subject to the provisions of ERISA. In the event of Plan termination, the participants would become fully vested and entitled to receive all amounts credited to their accounts.

5. Income Tax Status

The Plan has been designed using a volume submitter plan document designed by Fidelity Management & Research Co. (Fidelity Management). Fidelity Management has received a determination letter dated June 30, 2020, in which the Internal Revenue Service (IRS) stated that the Plan, as then designed, was in compliance with the applicable requirements of the IRC. The Plan has been amended since receiving the determination letter; however, the Plan Administrator believes that the Plan is currently designed and being operated in compliance with the applicable requirements of the IRC.

**AGIOS PHARMACEUTICALS 401(K) PLAN
NOTES TO THE FINANCIAL STATEMENTS
December 31, 2025 and 2024**



Accounting principles generally accepted in the United States of America require Plan management to evaluate tax positions taken by the Plan and recognize a tax liability for any uncertain positions that more likely than not would not be sustained upon examination by the IRS. The Plan Administrator has analyzed the tax positions taken by the Plan and has concluded that as of December 31, 2025, there are no uncertain positions taken, or expected to be taken, that would require recognition of a liability or disclosure in the financial statements. The Plan is subject to routine audits by taxing jurisdictions; however, there are currently no audits in progress for any tax periods.

6. Summary of Information Certified by the Trustee

The following is a summary of financial information and data certified by Fidelity, the trustee:

Statements of Net Assets Available for Plan Benefits at December 31, 2025 and 2024, except for participant and Company contributions receivable, if any;

Investment income and interest income from participant notes receivable on the Statement of Changes in Net Assets Available for Plan Benefits for the year ended December 31, 2025; and

Investment information provided in the supplemental schedule, Schedule of Assets (Held at End of Year) at December 31, 2025.

7. Related Party and Party-in-Interest Transactions

Certain plan investments are held and managed by Fidelity, the trustee of the Plan. Therefore, these transactions qualify as party-in-interest transactions. The Plan made direct payments to Fidelity for administrative services of \$65,424 for the year ended December 31, 2025. Participant notes receivable also qualify as party-in-interest transactions.

8. Differences from Form 5500

Differences between the Annual Return/Report of Employee Benefit Plan, Form 5500, and these financial statements are a result of different classifications between line items. Total Plan assets are in agreement.

AGIOS PHARMACEUTICALS 401(K) PLAN
NOTES TO THE FINANCIAL STATEMENTS
December 31, 2025 and 2024



9. Non-exempt Transactions

During 2025, the Employer failed to remit participant contributions of \$1,297 and loan repayments of \$385 to the Plan on a timely basis as prescribed in the applicable Department of Labor Regulations 29 CFR 2510.3-102. Defined contribution plans must remit employee contributions to the Plan as soon as they can be reasonably segregated from the Employer's general assets, but no later than the 15th business day of the month following the month in which the participant contributions are withheld or received by the Employer. The Employer remitted untimely participant contributions and loan repayments totaling \$1,682 due to the Plan during the year ended December 31, 2025. The Employer is currently working with its third-party administrator to calculate and remit any lost earnings associated with these late remittances.

AGIOS PHARMACEUTICALS 401(K) PLAN
ATTACHMENT TO SCHEDULE H, PART 4, LINE 4a-
SCHEDULE OF DELINQUENT PARTICIPANT CONTRIBUTIONS
Year Ended December 31, 2025

Employer Identification Number: 26-0662915
Plan Number: 001

<u>Identity of Party Involved</u>		<u>Relationship to Plan, Employer or Other Party-in-interest</u>			
* Agios Pharmaceuticals		Employer			
<u>Total that Constitutes Non-exempt Prohibited Transactions</u>					
	<u>Participant Contributions Transferred Late to Plan</u>	<u>Contributions Not Corrected</u>	<u>Contributions Corrected Outside VFCP</u>	<u>Contributions Pending Correction in VFCP</u>	<u>Total Fully Corrected Under VFCP and PTE-2002-51</u>
(1)	\$ 1,682	\$ 1,682	\$ -	\$ -	\$ -

(1) 2025 delinquent participant contributions and loan repayments, due to failed timely remittance as prescribed in the applicable Department of Labor Regulation 29 CFR 2510.3-102, as reported on the December 31, 2025 financial statements. Principal was transmitted during the year ended December 31, 2025. Lost earnings, if any, will be remitted and corrected during 2026.

* Indicates party-in-interest to the Plan.

AGIOS PHARMACEUTICALS 401(K) PLAN
ATTACHMENT TO SCHEDULE H, PART 4, ITEM 4i -
SCHEDULE OF ASSETS (HELD AT END OF YEAR)
December 31, 2025

Employer Identification Number: 26-0662915
Plan Number: 001

(a)	(b) Identity of issue, borrower, lessor or similar party	(c) Description of investment including maturity date, rate of interest, collateral, par, or maturity value	(e) Current value
	<u>Cash and Cash Equivalents:</u>		
*	Fidelity	Government Cash Reserves	\$ 1,540
	Vanguard	Federal Money Market Fund	1,121,044
	Total Cash and Cash Equivalents		<u>1,122,584</u>
	<u>Mutual Funds:</u>		
	American Funds	Balanced R6 Fund	535,890
	American Funds	New Perspective R6 Fund	1,272,300
	American Funds	New World Fund R6	1,581,093
	Allspring	Special Small Cap Value Fund - Class R6	595,870
	DFA	Inflation Protected Securities Portfolio	722,618
	DFA	Real Estate Securities Portfolio Institutional Class	765,389
*	Fidelity	Mid Cap Index Fund	2,476,501
*	Fidelity	Small Cap Index Fund	2,228,682
	Invesco	Gold & Special Minerals Fund	657,840
	JP Morgan	Large Cap Growth Fund R6	7,673,639
	JP Morgan	Mid Cap Growth Fund R6	1,311,914
	JP Morgan	U.S. Equity Fund R6	1,145,033
	PGIM	High Yield Fund R6	436,479
	PIMCO	Income Institutional Fund	1,062,430
	Vanguard	500 Index Fund Admiral Shares	14,485,120
	Vanguard	Developed Markets Index Fund Admiral Shares	1,783,782
	Vanguard	Explorer Fund Admiral Shares	1,108,018
	Vanguard	Growth Index Fund Admiral Shares	4,217,528
	Vanguard	Materials Index Fund Admiral Shares	287,514
	Vanguard	Target Retirement 2020 Fund	165,937
	Vanguard	Target Retirement 2025 Fund	3,200,955
	Vanguard	Target Retirement 2030 Fund	6,800,042
	Vanguard	Target Retirement 2035 Fund	12,388,474
	Vanguard	Target Retirement 2040 Fund	12,506,525
	Vanguard	Target Retirement 2045 Fund	15,585,998
	Vanguard	Target Retirement 2050 Fund	13,687,839
	Vanguard	Target Retirement 2055 Fund	12,217,903
	Vanguard	Target Retirement 2060 Fund	3,780,683
	Vanguard	Target Retirement 2065 Fund	343,584
	Vanguard	Target Retirement Income Fund	214,928
	Vanguard	Value Index Fund Admiral Shares	3,191,590
	Victory	Sycamore Established Value R6 Fund	911,037
	Voya	Intermediate Bond Fund R6	708,934
	Total Mutual Funds		<u>130,052,069</u>
	<u>Common Collective Trusts:</u>		
*	Fidelity	Managed Income Portfolio Class 1	383,371
	<u>Self-directed Brokerage Accounts:</u>		
*	Fidelity	BrokerageLink Fund	1,903,274
*	Participant Loans	Interest rates ranging from 4.25% to 9.50%; maturing at various dates through October 2033, collateralized by participant's vested account balance.	715,388
			<u>\$ 134,176,686</u>

* Indicates party-in-interest to the Plan.

Note: All investments are participant directed; therefore, the unit and cost columns have been omitted.